Water-soluble n-heterocyclic carbene metal nanoclusters
Water-soluble Au13 nanoclusters stabilized by N-heterocyclic carbene ligands address stability and solubility issues, enhancing their biocompatibility and efficacy for biomedical applications by using polyether, carboxylic acid, sugar, or protein moieties, and clickable groups for targeted delivery.
Patent Information
- Application Number
- PCT/CA2024/050729
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-06-01
- Filing Date
- 2024-05-30
- Publication Date
- 2024-12-05
AI Technical Summary
Current metal nanoclusters, particularly gold nanoclusters, face stability issues in aqueous solutions, limiting their biomedical applications due to oxidation and ligand exchange susceptibility, and lack of water solubility, which hampers their efficacy and increases toxicity.
Development of water-soluble metal nanoclusters stabilized by ditopic N-heterocyclic carbene ligands, specifically Au13 clusters with polyether, carboxylic acid, sugar, or protein moieties, enhancing their stability and biocompatibility, and enabling targeted delivery through clickable groups.
The water-soluble Au13 nanoclusters exhibit improved thermal stability, enhanced photoluminescence, and increased biocompatibility, facilitating effective biomedical applications such as bioimaging and cancer treatment with reduced toxicity.
Smart Images

Figure IMGF000004_0001 
Figure IMGF000005_0001 
Figure IMGF000011_0001
Abstract
Description
[0001] WATER-SOLUBLE N-HETEROCYCLIC CARBENE METAL NANOCLUSTERS
[0002] RELATED APPLICATIONS
[0003] This application claims the benefit of the filing date of United States Application No. 63 / 470,313, filed on June 1 , 2023, the contents of which are incorporated herein by reference in their entirety.
[0004] FIELD
[0005] The invention relates to metal nanoclusters that are soluble in aqueous media and have photoluminescent properties, and to methods of using such compounds.
[0006] BACKGROUND
[0007] Metal nanoclusters are atomically-precise class nanomaterials that, unlike metal nanoparticles, feature precise structures and well-defined molecular orbitals with discrete energy transitions and electronic structure. Clusters in which the only ligands are N- heterocyclic carbenes (NHCs) are limited. NHC-stabilized coordination clusters with gold atoms in the +1 state have been reported, but there are no examples of water-soluble NHC Au(0) / Au(l) nanoclusters.
[0008] The size regime between nanoparticles and molecular complexes is an interesting space occupied by atomically precise nanoclusters. These unique materials have sizedependent properties similar to other nanomaterials, but can be characterized by molecular techniques such as single crystal X-ray diffraction, nuclear magnetic resonance spectroscopy, and mass spectrometry. Unlike nanoparticles, which are a conglomeration of materials with an average size distribution, nanoclusters are routinely obtained as single molecules, with specific molecular weights, and optical properties characterized by individual electronic transitions rather than electron oscillations (plasmonics). Metal nanoclusters are atomically precise molecular-materials typically comprised of a few to several hundred metal atoms stabilized with organic ligands (and halides) and most often existing on the <2 nm scale. These clusters bridge the gap between materials and molecules, providing valuable insight into the behaviour of nanomaterials with the knowledge of precise structure that comes from molecular characterization tools.
[0009] SUMMARY
[0010] In one aspect, the invention provides a metal nanocluster comprising a plurality of ditopic ligands comprising a b / sN-heterocyclic carbene ligand and at least one water soluble moiety. In one embodiment, the metal nanocluster further comprises gold. In one embodiment, the metal nanocluster further comprises AU13. In one embodiment, the at least one water soluble moiety comprises a polyether, a carboxylic acid, a carboxylate, an ammonium group, a sugar, or a protein. In one embodiment, the polyether moiety comprises a polyethyleneglycol. In one embodiment, the polyether moiety is triethyleneglycol. In one embodiment, the carboxylic acid is a benzoic acid. In one embodiment, the carboxylic acid is a metal benzoate. In one embodiment, the sugar is glucose, galactose, mannose, lactose, maltose, or maltotriose. In one embodiment, the protein is an antibody. In one embodiment, the antibody is Pertuzumab. In one embodiment, the water soluble moiety is located on the wingtips of the bisNHC ligands. In one embodiment, the water soluble moiety is located on the backbone of the bisNHC ligands. In one embodiment, the nanocluster further comprises a targeting ligand. In one embodiment, the targeting ligand is a derivative of folic acid. In one embodiment the metal nanocluster further comprises at least one clickable group. In one embodiment, the clickable group is an azide.
[0011] In one embodiment, the nanocluster is selected from: [AU13(L)5X2]Y3where L is (benzyl- wingtip orthoxylyl-linker TEG-Me-backbone)NHC, [Aui3(L)5X2]Y3 where L is (Benzyl-wingtip napthyl-linker TEG-Me- backbone)NHC, [Aui3(L)5X2]Y3 where L is (4-azidobenzyl-wingtip orthoxylyl-linker TEG-Me-backbone)NHC, [AU13(L)5X2]Y3where L is (di-benzoic acid-wingtip ortho-xylyl-linker)NHC, [AU13(L)SX2]Y3where L is (di-ethyl-benzoate-wingtip ortho-xylyl-linker)NHC, [AU13(NHC)SX2]Y3where L is (4-Azidobenzyl-wingtip naphthyl-linker TEG-Me backbone)NHC, [AU13(bis-L)5X2]Y3where L is (Azidobenzyl-wingtip 1 ,8-napthyl-linker)NHC, [AU13(NHC)SX2]Y3where L is (di-benzoic acid-wingtip 1 ,8-dimethylnapthalene-linker)NHC, [AU13(L)SX2]Y3where L is (di-ethyl-benzoate-wingtip 1 ,8-dimethylnapthalene-linker)NHC, [AU13(NHC)SX2]Y3where L is (Folate-DIBO-wingtip benzyl-linker TEG-Me-backbone)NHC, [AU13(L)SX2]Y3where L is (Folate-BCN-wingtip benzyl-linker TEG-Me-backbone)NHC, [AU13(L)SX2]Y3where L is (DIBO-PEG4-Glucose-wingtip benzyl-linker)NHC, [AU13(L)SX2]Y3where L is (DI BO-TEG-Me- wingtip 1 ,8-naphthyl-linker)NHC, [AU13(L)SX2]Y3where L is (DIBO-TEG-Me-wingtip benzyllinker)NHC, or [AU13(L)SX2]Y3where L is (DIBO-TEG-Pertuzumab-wingtip benzyl-linker)NHC, where X is a monovalent ion and Y is a monovalent counterion (see simplified structures in Table 3). In one embodiment, X is a halide. In one embodiment, X is a chloride, or bromide.
[0012] In one aspect, the invention provides a complex comprising gold, and bisNHC ligands bearing a water soluble moiety. In one embodiment, the complex is selected from:
[0013]
[0014] Benzyl-wingtip orthoxylyl-linker TEG backbone NHC(AuCI)2.
[0015] In one embodiment, the metal nanocluster or complex is photoluminescent or electroluminescent.
[0016] In one aspect, the invention provides a photosensitizer comprising the metal nanocluster. In one aspect, the invention provides a method of photoredox catalysis comprising adding the metal nanocluster to a reaction mixture, and applying radiation to the reaction mixture. In one embodiment, radiation comprises visible light, UV light, heat, Gamma radiation or X-ray. In one aspect, the invention provides a photosensor comprising the metal nanocluster. In one aspect, the invention provides a solar cell comprising the metal nanocluster. In one aspect, the invention provides an electroluminescent device that comprises a metal nanocluster.
[0017] In one aspect, the invention provides a photoluminescent device that comprises the metal nanocluster. In one aspect, the invention provides a method of producing photoluminescence, comprising the steps of providing a photoluminescent metal nanocluster and applying radiation to the nanocluster whereby the nanocluster photoluminesces. In one aspect, the invention provides a method of imaging cells in tissue in a subject comprising administering to the subject a metal nanocluster, and applying radiation to cells that are desired to be imaged, wherein the nanoclusters in the cells photoluminesce. In one aspect, the invention provides a method of imaging cells in tissue comprising disposing the metal nanocluster into cells, and applying radiation, whereby the nanoclusters in the cells photoluminesce.
[0018] In one aspect, the invention provides a method of imaging cells in vitro comprising disposing the metal nanocluster into cells, and applying radiation, whereby the nanoclusters photoluminesce. In one aspect, the invention provides a method of imaging cells in vitro comprising disposing the metal nanocluster into cells, and applying radiation, whereby the nanoclusters can be detected by magnetic resonance imaging (MRI).
[0019] In one aspect, the invention provides a method of killing cells, comprising disposing the nanocluster into cells, and applying radiation, whereby the cells die. In one embodiment, radiation comprises visible light, UV light, heat, Gamma radiation, or Xray. In one aspect, the invention provides a method of producing electroluminescence, comprising the steps of providing a metal nanocluster and applying a voltage across the nanocluster whereby the nanocluster electroluminesces. In one aspect, the invention provides a method of photocatalysis or electrocatalysis comprising a metal nanocluster. In one embodiment, the metal nanocluster is stable in vivo, in aqueous media, in bodily fluids, and in simulated bodily fluids. In one aspect, the invention provides a biosensor comprising the metal nanocluster. In one aspect, the invention provides a radiation therapy adjuvant comprising the metal nanocluster. In one aspect, the invention provides a photodynamic therapy method comprising a step of administering the metal nanocluster, and using light to excite the metal nanocluster. In one aspect, the invention provides an X-ray photodynamic therapy method comprising a step of administering the metal nanocluster. In one aspect, the invention provides a cancer treatment therapy comprising a step of administering the metal nanocluster. In one aspect, the invention provides a bioimaging method comprising a step of administering the metal nanocluster. In one aspect, the invention provides a method of electrocatalysis comprising employing the metal nanocluster as an electrocatalyst. In one embodiment, the metal nanocluster is in solution or on a support. In one aspect, the invention provides a method of electrocatalysis comprising employing the metal nanocluster. In one embodiment, the metal nanocluster is a soluble electrocatalyst.
[0020] In one aspect the invention provides a water-soluble nanocluster selected from [AU13(L)5X2]Y3 where L is (benzyl-wingtip orthoxylyl-linker TEG-Me-backbone)NHC, [AU13(L)5X2]Y3 where L is (Benzyl-wingtip napthyl-linker TEG-Me- backbone)NHC, [AU13(L)5X2]Y3 where L is (4-azidobenzyl-wingtip orthoxylyl-linker TEG-Me-backbone)NHC, [AU13(L)5X2]Y3where L is (di-benzoic acid-wingtip ortho-xylyl-linker)NHC, [AU13(NHC)5X2]Y3where L is (4-Azidobenzyl-wingtip naphthyl-linker TEG-Me backbone)NHC, [AU13(NHC)5X2]Y3 where L is (di-benzoic acid-wingtip 1 ,8-dimethylnapthalene-linker)NHC, [AU13(L)5X2]Y3 where L is (DIBO-PEG4-Glucose-wingtip benzyl-linker)NHC, [AU13(L)5X2]Y3 where L is (DI BO-TEG-Me- wingtip 1 ,8-naphthyl-linker)NHC, [AU13(L)5X2]Y3 where L is (DIBO-TEG-Me-wingtip benzyllinker)NHC, or [AU13(L)5X2]Y3 where L is (DIBO-TEG-Pertuzumab-wingtip benzyl-linker)NHC, where X is a monovalent ion and Y is a monovalent counterion. BRIEF DESCRIPTION OF THE DRAWINGS
[0021] For a better understanding of the invention and to show more clearly how it may be carried into effect, reference will now be made, by way of example, to the accompanying drawings, wherein:
[0022] Fig. 1 shows a general synthetic route for monoalkylated TEG-Me-backbone benzimidazole.
[0023] Fig. 2 shows a schematic of a naming convention used herein for representative examples of a ligand and a metal nanocluster.
[0024] Fig. 3 shows a reaction scheme and structural formula of [AU13(L)5X2]X3where L is (DIBO-TEG-Pertuzumab-wingtip benzyl-linker)NHC.
[0025] Fig. 4 shows a photograph of a Western blot comparing DBCO-Pertuzumab and AuNanocluster (AuNC)-Pertuzumab, where antibody was detected by total protein stain and Immunoblot (IB) with a goat anti-human-IgG.
[0026] Fig. 5 shows a size exclusion chromatography (SEC) chromatogram of purified AuNC-Pertuzumab measuring absorbance at 280nm to detect protein products.
[0027] DETAILED DESCRIPTION OF EMBODIMENTS
[0028] Gold nanoclusters consist of a gold core (typically 10 - 300 atoms) surrounded by a protective layer of organic molecules. Their unique properties, including biocompatibility and high luminescence, have made them a promising material for multiple biomedical applications including bioimaging and biosensing. Additionally, gold nanoclusters are photosensitizers for use in cancer radiation therapy. Ultrasmall gold nanoclusters accumulate in tumor cells either passively through the permeable tumor vasculature, due to their small size, or by functionalization of the organic surface layer with tumor targeting agents. They are then able to strongly absorb high energy radiation to generate secondary electrons which accelerate DNA breakdown in cancer cells. Despite these benefits, the lack of stability of these clusters limits their efficacy and increases toxicity. Historically, organic ligands on the surface of these nanomaterials included phosphine and thiols which are vulnerable to oxidation and ligand exchange in physiological conditions. / V-heterocyclic carbenes have been shown to produce exceptionally stable gold nanoclusters. They also do not suffer the same susceptibility to exchange and oxidation that thiols have in vivo. Despite their obvious potential, their testing for biomedical application has been limited by their lack of water solubility.
[0029] Metal nanoclusters stabilized by ditopic ligands that include a plurality of bis(N- heterocyclic carbenes), and that have at least one water-soluble moiety are described herein. Importantly, these metal nanoclusters exhibit solubility in aqueous solution. Ditopic ligands protect the metal core of the nanocluster. Ditopic ligands are capable of coordination at two separate sites. There are several different ditopic ligands exemplified herein. The metal nanoclusters are protected by five identical ditopic ligands, each ligand has at least one NHC. NHCs are neutral ligands that include a divalent carbon with six valence electrons in its valence shell and at least one nitrogen within a ring.
[0030] Previous metal nanoclusters protected by b / 's(A / -heterocyclic carbenes) are different from embodiments described herein. For example, most previous NHC metal nanoclusters are soluble only in organic solvent and not in water. Certain N-heterocyclic carbene stabilized gold nanoclusters have been studied. Recent reports have demonstrated the use of b / sNHCs ligands gave metal clusters with outstanding thermal stability and some of the highest reported photoluminescence quantum yields (PLQY) among AU13 nanoclusters. This is the first report of such metal nanoclusters that are soluble in aqueous solution.
[0031] As described herein, water-soluble AU13 nanoclusters protected by NHC ligands have been synthesized and characterized. Their water solubility properties aid in biomedical testing and application of this material.
[0032] The properties of metal nanoclusters in cells are highly dependent on the properties of the organic protection group. Several different b / s(N-heterocyclic carbenes were prepared and studied. Their structural formula as well as structures of certain other compounds that were used in the syntheses outlined herein, appear in Table 1. Gold complexes (i.e. , Au?) that were prepared and characterized are shown in Table 2. Structural formulae for water- soluble gold nanoclusters (AU13) protected by b / s( / V-heterocyclic carbenes) are shown in Table 3, and synthetic steps are outlined in the Working Examples.
[0033] To simplify discussion of the components of ligands and gold clusters, a naming convention has been used herein (see Fig. 2 for a schematic), including: the term linker for the central moiety that connects one NHC to the other via a nitrogen atom of each NHC ring; the term wingtip for the moiety that is attached to the other nitrogen atom of each NHC; the term backbone for the C6ring of the NHC fused rings, and the term water-soluble moiety for a functional group that is bonded to the ligand.
[0034] Non-limiting examples of wingtip groups include CH2Aryl, where Aryl is a substituted or unsubstituted monocyclic aromatic including phenyl, tolyl (o, m, p), xylyl, ort / jo-xylyl, or any heteroaromatic, wherein substituents include alcohol, ether, amine, nitro, ester, acetate, alkyl, and / or haloalkyl groups.
[0035] Non-limiting examples of linkers include ort / 70-xylyl, naphthyl, 1 ,1'-(naphthalene-1 ,8- diylbis(methylene)), 1 ,T-(naphthalene-2,7-diylbis(methylene)), C3H6, CH2-G-CH2, where G comprises CMe2, C(aliphatic) 2, C(aryl)2, O, N, S, heteroatom, or similar compounds that are substituted or unsubstituted and may include heteroatoms that do not interfere with the binding of the linker to the cluster.
[0036] Several water-soluble metal nanoclusters are described herein, and they are protected by NHC ligands that include water-soluble functional groups. There are two main locations where water-soluble functional groups were situated on the b / sNHC ligands. These locations were on aromatic wingtip groups, which orient the functional groups at the top and bottom of the nanocluster; and on backbone of the NHC which placed the functional groups around the equator of the nanocluster. Examples of water-soluble functional groups include: polyether (e.g., polyethyleneglycol, triethyleneglycol, tetraethyleneglycol), a carboxylic acid (e.g., benzoic acid), a carboxylate, an ammonium group, a sugar (e.g., glucose, galactose, mannose, lactose, maltose, or maltotriose), or a protein (e.g., antibody).
[0037] The polyethylene glycol (PEG) functional group has been used to impart water solubility to gold nanoparticles and has been found to produce nanoparticles which have high tumour accumulation. It was also found that smaller gold nanoparticles containing PEG have better tumour accumulation than larger clusters. In some embodiments, triethyleneglycol was used as the water soluble moiety. Triethylene glycol monomethyl ether (TEG-Me) is a water soluble functional group that is similar to PEG, but that is smaller in size. As seen in Table 3, one embodiment of b / sNHC nanoclusters include two Triethylene glycol monomethyl ether (TEG-Me) groups on the wingtips. One embodiment, includes four TEG-Me groups on the backbone. One embodiment has two glucose groups on the wingtips. Another embodiment has with two COOH groups on the wingtips.
[0038] Carboxylic acid moieties are known to increase water solubility in medicinal chemistry as they can be deprotonated at physiological pH, thus bearing a negative charge which can be easily solvated by water. Furthermore, carboxylic acids can be used as a point of attachment for polypeptides via peptide coupling strategies. As such, carboxylic acid functionalized clusters have easily tunable properties.
[0039] Polypeptides have rich and diverse properties that can be tuned by altering their sequence of amino acids. In one embodiment, nanoclusters which include bisNHC ligands with four TEG-Me groups located on the NHC backbone and antibodies located on the wingtips have been prepared and characterized (see Table 3, Figs 3-5, and Example 7G).
[0040] Thermal and physiological stability of the clusters were tested in experiments using UV-vis spectroscopy. The clusters exhibited good thermal stability. The following three clusters were stable over 48 h in acetonitrile at 70 ° C: [AU13(L)5CI2]CI3where L is (benzyl- wingtip orthoxylyl-linker TEG-Me- backbone)NHC (see Example 6A); [AU13(L)5Br2]Br3where L is (Benzyl-wingtip orthoxylyl-linker TEG-Me backbone)NHC (see Example 6B); [AU13(L)5Br2]Br3 where L is (Benzyl-wingtip naphthyl-linker TEG-Me- backbone)NHC (see Example 60). The following two clusters were stable in 1 :1 EtOH:H2O at 90° Celsius with 30 equivalents of KOH: [AU13(L)5Br2]Y3where L is (di-ethyl-benzoate-wingtip orthoxylyl-linker)NHC and Y is a counterion (e.g., Cl, Br, BF4, or PF6) (see Example 6J); and [AU13(L)5Br2]Y3where L is (dibenzoic acid-wingtip orthoxylyl-linker)NHC and Y is a counterion (e.g., Cl, Br, BF4, or PF6) (see Example 6M).
[0041] A benefit of metal nanoclusters with a TEG-Me functional group on the backbone is that the wingtip groups are still available for functionalization. Clusters were also made water soluble through “click” chemistry. To do this, NHCs were synthesized to contain azidated wingtip moieties, enabling click functionality. Strain-promoted alkyne-azide cycloaddition (SPAAC) is a type of bioorthogonal reaction which is able to bond two molecules together easily and under mild conditions. In one embodiment, an azide group and a strained cyclooctyne (di benzocyclooctyne (DIBO) or aza-dibenzocyclooctyne (DBCO)) were used to functionalize nanoclusters. Facile functionalization was investigated using click chemistry to synthesize gold clusters with 4-azidobenzyl wingtip groups (see Table 3). Click reactions were used to prepare clusters with glucose, TEG-Me, folic acid and antibodies appended (see Table 3).
[0042] The NHC ligand was synthesized using standard organic chemistry techniques accommodating each additional “clickable” substituent on the NHC. In one embodiment, the NHC ligand was prepared with an azide on the wingtip and included stable benzimidazolium based cores. From NHC salt, the corresponding gold complex (NHC-Au-CI) was prepared using a base (K2CO3) and the addition of (SMe2)AuCI using literature procedures. Reduction of the gold complex (NHC-Au-CI) produced AU13 nanoclusters stabilized by NHC ligands. The AU13 clusters were purified and dialyzed to isolate the clusters as a monodisperse species. Characterization techniques including NMR, ESI-MS, FT-IR, UV-Vis were employed to gain a full picture of the molecular structure of these species.
[0043] A second “clickable” NHC-protected cluster with enhanced photoluminescent properties was also prepared in a similar method. This embodiment used a ir-extended naphthyl linker (in place of the previously employed benzyl linker). This cluster has an enhanced quantum yield which further enabled the clusters to be viable nanomedical tools. Briefly, the gold complex was prepared by reaction of the NHC salt with AuSMe2CI and K2CO3. The resulting mixture was purified and reduced to afford the desired cluster.
[0044] Clickable clusters were functionalized using four moieties, TEG-Me, TEG-sugar (where sugar refers to glucose, mannose, galactose, lactose, maltose, maltotriose), folate, and antibodies. The first group that was attached was TEG-Me, which provided water solubility. Next folate and sugar groups were attached which also provided solubility while facilitating targeting as the folate receptors and glucose transporters (GLUT). These receptors and transporters are overexpressed on cancer cells making them ideal subjects of receptor-targeted cancer treatments. The antibody Pertuzumab, a recombinant humanized monoclonal antibody that targets human epidermal growth factor receptors (HER), was also attached. This antibody enabled solubility and facilitated targeting since many cancers overexpress HERs. TEG-Me, folate, and glucose derivatives were functionalized by the strained alkyne DIBO and Pertuzumab was functionalized by the strained alkyne DBCO. DIBO functionalization on TEG-Me, folate, and glucose was achieved by synthesizing a TEG- Me-amine, folate-amine and glucose-amine species which allowed for controlled functionalization at the intended site. The aminated folate and glucose species were attached to the strained alkyne using DIBO-pNP (pNP refers to para-nitrophenol) to afford Folate-DIBO and Glucose-DIBO. To functionalize Pertuzumab with DBCO, the antibody was subjected to mild reduction conditions to afford free inter-chain Cysteine residues, which were then attached to the strained alkyne using DBCO-maleimide through a cysteine- maleimide reaction, affording the DBCO-Pertuzumab. The DIBO functionalized TEG-Me, folate, glucose and DBCO-Pertuzumab were reacted with azide containing clusters to induce the ring closing click reaction affording an AU13cluster with the TEG-Me or targeting molecules on the outer surface. This technique attached folate, glucose and Pertzumab molecules to the cluster without destroying the cluster entity while also leaving the functional receptor-binding part of the biomolecules (folate, glucose and antibody) intact. The clusters have been charactered using: NMR, high-resolution mass spectrometry; or SDS-PAGE, Western Blotting and Size-Exclusion Chromatography (for antibody clusters); luminescence and emission studies; and UV-Vis spectroscopy and ex vivo stability studies. With these biomolecules, DIBO- and DBCO-molecules underwent a copper-free click reaction, which refers to a ring closing reaction that bound azide to the alkyne group without the need for biologically incompatible copper catalysts.
[0045] The following working examples further illustrate the invention and are not intended to be limiting in any respect.
[0046] Example 1. Synthesis of bio-active molecules for attachment to gold nanoclusters
[0047] The above synthesis was performed according to literature procedure (Chem. Biochem.
[0048] 2011 August 16; 12(12): 1912-1921. doi:10.1002 / cbic.201100117). The product, DIBO-pNP, matched the published characterization. Example 1 B. Synthesis of Folate-Diamine
[0049] Folate-Diamine
[0050] Synthesis of folate-diamine was performed according to a modified literature procedure (Org. Biomol. Chem., 2014,12, 3181-3190). Folic acid (640 mg, 1.34 mmol) was dissolved in DMSO (degassed and dried over 3A molecular sieves). N-hydroxysucinimide (308 mg, 2.67 mmol) and DCC (552 mg, 2.67) were added rapidly under positive flow of Ar. The reaction was stirred overnight at room temperature for 16 hours. The solution was filtered slowly through a celite plug and the clear DMSO solution returned to the reaction vessel. Triethylamine (0.376 mL) and N-Boc ethylene diamine (429 mg, 6 mL) were added were added. The reaction was stirred at room temperature overnight. The desired product was precipitated from the reaction mixture using 20% acetone in diethylether and collected by centrifugation. The yellow powder was washed 10 times with 20% acetone in diethylether to remove all DMSO. Finally, the product was dissolved in minimal amounts (5 mL) trifluoroacetic acid and stirred for two hours. The trifluoacetic acid was removed by blown air and the residue was dissolved in DMF. Triethylamine was added until the power precipitated. The product, folate-diamine, was collected by centrifugation and washed with 3 x 20% acetone in diethylether.1H NMR confirmed full deprotection of the BOC group.1H NMR 8.64 (s, 1H), 7.51-7.73 (1H, m), 6.65 (d, 2H), 4.47 (s, 2H), 4.31 (s, 1H), 2.98-3.21 (m, 4H), 1.81-2.21 (m, 4H).
[0051] Example 1C. Synthesis of tetraethyleneglycol p-toluenesulfonic acid ester
[0052] Tetraethyleneglycol p-toluenesulfonic acid ester Tetraethyleneglycol p-toluenesulfonic acid ester was synthesized following an adapted literature procedure (see Chirkin, E., et al., Angewandte Chemie International Edition 2017, 56 (42), 13036-13040. DOI: 10.1002 / anie.201707536 ). Tetraethylenglycol (9.1 mL, 52 mmol, 10.0 eq.) was dissolved in DCM (10 mL) and cooled to 0 °C. Tosyl chloride (1.0 g, 5.2 mmol, 1.0 eq.) and triethylamine (1.1 mL, 7.8 mmol, 1.5 eq.) were added and the mixture was stirred over night at room temperature. The organic layer was washed with water (3x 10 mL), brine (1x 10 mL), dried over sodium sulphate and the solvent was removed in vacuo to afford the product (1.78 g, 5.1 mmol, 98%) as a colorless oil. C15H24O7S, MW: 348.4100 g / mol.1H-NMR (400 MHz, CDCI3): δ = 7.80 (d, J = 8.3 Hz, 2H), 7.34 (d, J = 8.0 Hz, 2H), 4.16 (t, J = 4.8, 2H), 3.74 - 3.54 (m, 14 H), 2.44 (s, 3H).
[0053] Example 1 D. Synthesis of 2-(2-(2-(2-azidoethoxy)ethoxy)ethoxy)ethanol
[0054] 2-(2-(2-(2-azidoethoxy)ethoxy)ethoxy)ethanol was synthesized following an adapted literature procedure (see Chirkin, E., ef al., Angewandte Chemie International Edition 2017, 56 (42), 13036-13040. DOI: 10.1002 / anie.201707536 ). Tetraethyleneglycol p- toluenesulfonic acid ester product 38 (1.72 g, 4.9 mmol, 1.0 eq.) was dissolved in DMF (20 ml_), sodium azide (353 mg, 5.4 mmol, 1.1 eq.) was added and the mixture was stirred at 60 °C over night. After completion of the reaction DMF was removed in vacuo to a 1 / 3 of its initial volume, water (10 mL) was added and the aqueous layer was extracted with EtOAc (3x 10 mL). The combined organic layers were dried over sodium sulphate and the solvent was removed in vacuo to afford 2-(2-(2-(2-azidoethoxy)ethoxy)ethoxy)ethanol (847 mg, 3.6 mmol, 73%) as a pale yellow oil. C8H17N3O5, MW: 235.2400 g / mol.1H-NMR (300 MHz, CDCI3): δ = 3.76 - 3.59 (m, 14 H), 3.40 (t, J = 5.0, 2H).
[0055] Example 1 E. Synthesis of P-D-glucose pentaacetate
[0056] P-D-glucose pentaacetate
[0057] P-D-Glucose pentaacetate was synthesized following an adapted literature procedure (see Kofsky, J. M., et al., European Journal of Organic Chemistry 2022, 2022 (29). DOI: 10.1002 / ejoc.202200108.) To a solution of glucose (1.0 g, 5.6 mmol, 1.0 eq.) and 4- (Dimethylamino)pyridine (0.14 g, 1.1 mmol, 0.2 eq.) in pyridine (7 mL) was added acetic anhydride (5.2 mL, 55.5 mmol, 10.0 eq.) and the mixture was stirred at room temperature (RT) for 4 h. The reaction progress was followed by TLC and after completion, Ethylacetate (15 mL) was added. The organic layer was washed with water (1 x 15 mL), 10% HCI (2 x 15 mL), sat. NaHCOs (1 x 15 mL), brine (1 x 15 mL), dried over sodium sulphate and the solvent was removed in vacuo to afford p-D-glucose pentaacetate (2.02 g, 5.31 mmol, 96 %) as a colourless solid. C16H22O11, MW: 390.3410 g / mol.1H-NMR (400 MHz, CDCI3): δ = 6.33 (d, J = 3.7 Hz , 1H), 5.47 (t, J = 9.9 Hz, 1 H), 5.14 (t, J = 9.9 Hz, 1 H), 5.12 - 5.07 (m, 1H), 4.27 (dd, J = 4.2, 12.6 Hz, 1H), 4.16 - 4.06 (m, 2H), 2.18 (s, 3H), 2.09 (s, 3H), 2.04 (s, 3H), 2.03 (s, 3H), 2.02 (s, 3H).
[0058] Example 1 F. Synthesis of D-glucose tetraacetate
[0059] D-glucose tetraacetate
[0060] Anomeric deprotection of glucose pentaacetate was performed following an adapted literature procedure (see Kofsky, J. M., et al., European Journal of Organic Chemistry 2022, 2022 (29). DOI: 10.1002 / ejoc.202200108.) To a solution of P-D-glucose pentaacetate (1.5 g,
[0061] 3.8 mmol, 1.0 eq.) in dry THF (20 ml_), was added 7N NH3 in MeOH (8.2 ml_, 57.6 mmol, 15.0 eq.) under an argon atmosphere at 0 °C. The reaction progress was followed by thin layer chromatography and after 3 h excess ammonia was removed by blowing air over the mixture. DCM (30 mL) was added and the organic phase was washed with saturated NaHCO3(2 x 30 mL), brine (1 x 30 mL), dried over sodium sulphate and solvent was removed in vacuo to afford yield a mixture of a- and P-D-Glucose tetraacetate (1.04 g, 3.00 mol, 79%) as colourless solid. P-Anomer: C14H20O10, MW: 348.3040 g / mol.1H-NMR (400 MHz, CDCI3): δ = 5.54 (t, J = 9.8 Hz, 1 H), 5.47 (br, 1 H), 5 = 5.09 (t, J = 9.7 Hz, 1 H), 4.92 (dd, J = 3.5, 10.1 Hz, 1 H), 4.30 - 4.22 (m, 2H), 4.17 - 4.10 (m, 1H), 2.10 (s, 3H), 2.09 (s, 3H), 2.04 (s, 3H), 2.02 (s, 3H).
[0062] Example 1G. Synthesis of 2,3,4,6-tetra-O-acetyl-P-D-glucopyranosyl trichloroacetimidate
[0063] 2,3,4,6-Tetra-O-acetyl-P-D-glucopyranosyl trichloroacetimidate Tetraacetyl-glucoseimidate was synthesized following an adapted literature procedure (see Kofsky, J. M., et al., European Journal of Organic Chemistry 2022, 2022 (29). DOI: 10.1002 / ejoc.202200108.) A solution of P-D-Glucose tetraacetate (1.0 g,
[0064] 2.9 mmol, 1.0 eq.) 15-17 in dry DCM (30 mL) was stirred over 4 A molecular sieves under an Argon atmosphere for 30 minutes. The mixture was cooled to 0 °C and trichloroacetonitrile (2.3 mL, 23.0 mmol, 8.0 eq.) and K2CO3(1.6 g, 11.5 mmol, 4.0 eq.) were added. The mixture was stirred for 3 h at room temperature and the progress of the reaction was followed by TLC. After completion, the mixture was filtered through celite and the residue was washed with DCM (2x 10 mL). The solvent was removed in vacuo and the crude product was purified using column chromatography (7:3 hexanes / EtOAc) to afford the p-product (1.04 g, 2.11 mmol, 73 %) as a colourless solid. C16H20CI3NO10, MW: 492.6830 g / mol.1H-NMR (600 MHz, CDCI3): δ = 8.69 (s, 1 H), 6.57 (d, J = 3.7 Hz, 1 H), 5.57 (t, J = 9.8 Hz, 1 H), 5.19 (t, J = 9.9 Hz, 1 H), 5.14 (dd, J = 3.7, 10.2 Hz, 1H), 4.28 (dd, J = 4.2, 12.4 Hz, 1H), 4.23 - 4.20 (m, 1H), 4.15 - 4.10 (m, 1 H), 2.08 (s, 3H), 2.05 (s, 3H), 2.04 (s, 3H), 2.04 (s, 3H).
[0065] Example 1 H. Synthesis of 2-[2-[2-(2-azidoethoxy)ethoxy]ethoxy]ethyl-2,3,4,6-tetra-O- acetatyl-p-D-Glucopyranoside
[0066] 2-[2-[2-(2-azidoethoxy)ethoxy]ethoxy]ethyl-2,3,4,6-tetra-0-acetatyl-p-D- Glucopyranoside
[0067] The above product was synthesized following an adapted literature procedure (see Vohra, Y., et al., Org. Lett. 2008, 10, 15, 3247-3250. A solution of the glucosyl-imidate (1.0 g, 2.0 mmol, 1.0 eq.) and 2-(2-(2-(2-azidoethoxy)ethoxy)ethoxy)ethan-1-ol 25 (1.42 g, 8.1 mmol, 4.0 eq.) in dry DCM (8 mL) was stirred over 4 A molecular sieves under an argon atmosphere for 30 minutes. The mixture was cooled to 40 °C and triflic acid (36 pL, 0.4 mmol, 0.2 eq.) was added. The reaction progress was followed by thin layer chromatography (TLC). After completion of the reaction, sat. NaHCO3(1 mL) was added, the mixture was filtered through CELITE™ and the solids were washed with DCM (2x 5 mL). The solvent was removed in vacuo and the crude product was purified using column chromatography (hexanes / EtOAc) to afford the product (605 mg, 1.10 mmol, 55 %) as a colourless oil. C22H35N3O13, MW: 549.5300 g / mol.1H-NMR (600 MHz, CDCI3): δ = 5.20 (t, J = 9.5 Hz, 1H), 5.08 (t, J = 9.7 Hz, 1 H), 4.99 (dd, J = 8.0, 9.5 Hz, 1 H), 4.61 (d, J = 8.0 Hz, 1 H), 4.26 (dd, J = 4.7, 12.3 Hz, 1H), 4.14 (dd, J = 2.2, 12.3 Hz, 1H), 3.94 (td, J = 4.3, 11.0 Hz, 1 H), 3.78 - 3.62 (m, 14 H), 3.39 (t, J = 5.1 Hz, 2H), 2.09 (s, 3H), 2.05 (s, 3H), 2.02 (s, 3H), 2.00 (s, 3H).
[0068] Example 11. Synthesis of 2-[2-[2-(2-Azidoethoxy)ethoxy]ethoxy]ethyl -D-glucopyranoside
[0069] 2-[2-[2-(2-Azidoethoxy)ethoxy]ethoxy]ethyl p-D-glucopyranoside
[0070] The acetylated glucopyranoside (0.5 g, 0.91 mmol, 1.0 eq.) was dissolved in MeOH (5 mL), a solution of NaOMe in MeOH (25 wt%) was added dropwise until pH > 10 and the mixture was stirred at room temperature for 1 h. After completion of the reaction Amberlite H+ IR-120 was added until pH = 7. The mixture was filtered through CELITE™ and the residue was washed with MeOH (3x 1 mL). The solvent was removed in vacuo to afford the product (333 mg, 0.87 mmol, 96 %) as colorless oil. C14H27N3O9, MW: 381.3820 g / mol.1H-NMR (600 MHz, CDCI3): δ = 4.38 (d, J = 7.7 Hz, 1 H), 4.05 - 4.01 (m, 1 H), 3.89 (dd, J = 2.8, 11.8 Hz, 1 H), 3.82 (dd, J = 4.5, 11.9 Hz, 1 H), 3.79 - 3.75 (m, 1H), 3.74 - 3.65 (m, 14H), 3.62 (t, J = 4.5 Hz, 1 H), 3.58 (d, J = 9.2 Hz, 1 H), 3.54 (t, J = 9.0 Hz, 1 H), 3.43 - 3.36 (m, 2 H).
[0071] Example 1J. Synthesis of 2-[2-[2-(2-Aminoethoxy)ethoxy]ethoxy]ethyl p-D-glucopyranoside
[0072] 2-[2-[2-(2-Aminoethoxy)ethoxy]ethoxy]ethyl P-D-glucopyranoside
[0073] The azide (0.25 g, 0.67 mmol, 1.0 eq.) was dissolved in MeOH (5 mL), Pd / C (50 mg, 10 wt%) was added and the mixture was stirred at room temperature under an H2 atmosphere for 2 h. After completion of the reaction the mixture was filtered through CELITE® and the residue was washed with MeOH (3x 1 mL). The solvent was removed in vacuo to afford the amine (227 mg, 0.64 mmol, 95 %) as colorless oil. C14H29NO9, MW: 355.3840 g / mol.1H-NMR (600 MHz, CDCI3): δ = 4.26 (d, J = 7.8 Hz, 1 H), 3.99 - 3.95 (m, 1 H), 3.81 (d, J = 11.8 Hz, 1 H), 3.70 - 3.57 (m, 12H), 3.50 (t, J = 5.3 Hz, 2H), 3.32 - 3.28 (m, 1 H), 3.27 - 3.25 (m, 1 H), 3.24 - 3.21 (m, 1 H), 3.14 (dd, J = 7.8, 9.2 Hz, 1 H), 2.77 (t, J = 5.3 Hz, 2H).
[0074] Example 1 K. Synthesis of Glucose-DIBO conjugate
[0075] Glucose-DIBO conjugate
[0076] Synthesis of Glucose-DIBO conjugate was performed following an adapted literature procedure (see Mbua, N. E., et al., Chem. Bio. Chem. 2011 , 72 (12), 1912-1921. DOI: 10.1002 / cbic.201100117). The free amine (50.0 mg, 0.14 mmol, 1.0 eq.), DIBO-Nitrophenol (60.0 mg, 0.15 mmol, 1.1 eq.) and triethylamine (39 pl, 0.28 mmol, 2.0 eq.) were dissolved in DCM (5 mL) and stirred for 12 h at room temperature. After completion of the reaction the solvent was removed in vacuo and the crude product was purified using column chromatography (DCM / MeOH, 9:1) to afford the product (53 mg, 89 μmol, 63 %) as a colorless oil. C31H39NO11, MW: 601.6490 g / mol.1H-NMR (600 MHz, CDCI3): δ = 7.52 (d, J = 6.8 Hz, 1 H), 7.37 - 7.24 (m, 7H), 5.97 (d, J = 5.6 Hz, 1 H), 5.50 - 5.45 (m, 1 H), 4.60 (d, J = 22.0 Hz, 1 H), 4.36 - 4.31 (m, 1 H), 3.99 - 3.93 (m, 1 H), 3.85 - 3.78 (m, 2H), 3.74 - 3.49 (m, 15H), 3.42 - 3.27 (m, 3H), 3.17 (d, J = 15.1 Hz, 1H), 2.90 - 2.82 (m, 1H).
[0077] Example 1 L. Synthesis of Folate-DIBO and Folate-BCN
[0078] Folate-DIBO (upper) and Folate-BCN (lower)
[0079] As referred to herein, the term BCN refers to bicyclononyne. Folate diamine (10 mg, 0.0207 mmol)(see Example 1 B) was dissolved in DMSO (degassed and dried over 3A molecular sieves). DIBO-pNP or BCN-pNP (1.5 eq) was added under positive Argon pressure with pyridine (5 eq). The reaction was stirred at room temperature overnight for 16 hours. The resulting solution was poured into 20 mL 20% acetone in diethylether. The resulting thin yellow powder was collected by centrifugation and washed 5 times with 20% acetone in diethylether.1H NMR (Folate BCN): 2.73 (d, 2H), 3.08 (d, 6H), 4.49 (s, 2H), 5.27 (s, 1 H), 6.63 (t, 2H), 6.93 (bs, 2H), 7.33-7.73 (m, 12H), 7.95 (d, 2H), 862 (d, 1 H).1H NMR (Folate DIBO): 8.64 (s, 1H), 7.51-7.73 (1H, m), 7.29-7.47 (8H, m, DIBO), 6.65 (d, 2H), 4.47 (s, 2H), 4.31 (s, 1H), 2.98-3.21 (m, 4H), 1.81-2.21 (m, 4H).
[0080] Example 1 M. Synthesis of TEG-tosylate
[0081] TEG-tosylate Methoxytriethylene glycol (8.55 mL, 0.053 mol) was dissolved in 108 mL H2O and cooled to 0. Tosyl chloride (20.37 g, 0.11 mmol) in 36 mL THF was added dropwise over 10 minutes. The reaction was stirred at room temperature overnight. The resulting solution was extracted with 3 x 35 mL Et2<D. The combined organic phases were dried with MgSO4, filtered and concentrated to afford a green oil (10.52 g, 80%).1H NMR: 3.35 (s), 3.36-3.53 (m), 4.13 (s), 7.47 (d), 7.80 (d).
[0082] Example 1 N. Synthesis of TEG-Me-Azide
[0083] TEG-Me-Azide
[0084] TEG-Me-tosylate (2.5 g, 7.86 mol) was dissolved in 3 mL DMF. NaNa (2.55 g, 39.39 mol) was added and the reaction was stirred at 60 overnight. The resulting solution was extracted with 3 x 35 mL CH3CI, dried with MgSO4 and filtered. The organic extracts were dried under reduced pressure to afford a yellow oil (0.94 g, 63%).1H NMR: 3.39 (t), 3.46 (t), 3.56 (m), 3.62 (t).
[0085] Example 1 Q. Synthesis of TEG-Me-Amine
[0086] TEG-Me- Amine
[0087] TEG-Me-azide (3.84 g, 0.02 mol) was dissolved in 65 mL distilled THF. Solution was stirred for 5 hours at room temperature after which 1.5 eq. degassed H2O was added. The reaction was heated to reflux and stirred overnight. The resulting solution was concentrated under reduced pressure. The residue was dissolved in toluene (100 mL) and extracted with 3 x 100 mL H2O. The water was removed under reduced pressure to afford the product as a yellow oil (81% yield, 2.64 g).1H NMR: 2.81 (m), 3.41 (m), 3.59 (m), 3.64 (m), 3.70 (m), 4.73 (m).
[0088] Example 1 P. Synthesis of TEG-Me-DIBO
[0089] TEG-Me-DIBO
[0090] TEG-Me-amine (14.13 mg, 0.086 mmol) was dissolved in distilled CH2CI2 and cooled to 0°C. Then 4 eq. pyridine were added under positive Ar<g) pressure. DIBO-pNP (40 mg, 0.103 mmol) was added and the reaction was stirred for 4 hours at room temperature. The resulting product was purified by column chromatography to afford the desired product as a yellow oil. (35 mg, 83%).1H NMR: 7.20-7.36 (m, 8H, aromatic), 5.74 (bs, 1 H), 3.65-3.48 (m, 8H), 3.40 (m, 2H), 3.15 (d, 1H), 2.56-2.99 (m, 6H).
[0091] Example 1Q. Expression of Pertuzumab Antibody
[0092] Pertuzumab expression was carried out in Expi-293 cells following Thermo Fisher’s user guide for the Expi-293TM Expression System with a 100 mL culture volume. Transfection was performed with two pcDNA3.4-TOPO plasmids, containing either the heavy or light chain Pertuzumab gene sequence. Five days after transfection, proteins were harvested and subsequently centrifuged at 4500 x g for 30 min at 4 °C. The supernatant was filtered (0.45-μm filter) and diluted to the composition of the binding buffer (20 mM sodium phosphate, pH 7.0) and then immediately loaded onto a protein G column for purification pre-equilibrated and washed with 10 column volumes (GV) of binding buffer (20 mM sodium phosphate, pH 7.0). Sample was applied to the column and then washed with 10 CV binding buffer. Next, proteins were eluted with 10 CV elution buffer (0.1 M glycine-HCI, pH 2.7) and collected in neutralization buffer (1 Tris-HCI, pH 9.0) on ice. Purified fractions were buffer exchanged into phosphate buffered saline (PBS) and concentrated before storage at a final concentration of 10 mg / mL for long-term storage at -80 °C. Expression yielded 30 mg Pertuzumab per 100 mL culture.
[0093] Example 1 R. -DBCO-Pertuzumab Preparation
[0094] Refering to Figure 3 (first reaction arrow), to reduce cysteines, Pertuzumab (500 ug) was suspended to a final concentration of 6.5 uM in a mixture of PBS with fresh TCEP (80 μM) and EDTA (1000 μM). The reaction was incubated for 2 h at 37 °C, rocking end-over- end. Maleimide-PEG4-DBCO was then added in 6 times molar excess over each cysteine. The mixture was reacted overnight at 37 °C, rocking end-over-end. To remove excess Maleimide-PEG4-DBCO, samples were buffer exchanged with PBS by spin-filtration using a 30 kDa molecular weight cut-off centrifugation filter.
[0095] Example 2. Synthesis of N-Heterocyclic Carbenes Example 2A. Synthesis of 5,6-bis(2-(2-(2-methoxyethoxy)ethoxy)ethoxy)-1 H- benzo[d]imidazole
[0096] 5,6-bis(2-(2-(2-methoxyethoxy) ethoxy)ethoxy)-1H-benzo[d]imidazole
[0097] To a 1000 mL round botom flask, 1 ,2-bis(2-(2-(2-methoxyethoxy)ethoxy)ethoxy)-4,5- dinitrobenzene (14.5 g, 29.4 mmol, 1 eq.), synthesized by published procedure (Chem. Commun., 2011 ,47, 8226-8228), was added followed by 1 ,4-dixoane (330 mL). The flask was cooled in an ice bath for 30 minutes. SnCl2«2 H2O (40.5 g, 179 mmol, 6.1 eq.) was added to a beaker and concentrated HCI (84 mL) was added and stirred until it is mostly suspended in solution. The dissolved SnCh solution was slowly added to the flask. The solution was then removed from the ice bath and warmed up to room temperature and stirred 24 h. 2.5 M NaOH solution was added until the solution was basic as seen on a pH strip. The reaction mixture was placed in a 1 L beaker. 200 mL of DCM was then added, and the organic layer was extracted 10 times (~2000 mL total). The DCM was then concentrated to dryness in vacuo. The residue was used immediately for the next step.
[0098] To the 1000 mL round bottom flask with the residue, concentrated formic acid (100 mL) was added. The flask was then heated at 82 °C overnight. The flask was then cooled to room temperature and the formic acid was removed by rotary evaporator. The residue was then suspended in 300 mL of H2O and solid NaHCOs was added until the bubbling ceased and the pH was about 7 by pH strip. The solution was then extracted with DCM in a 1 L separatory funnel (300 mL x 5), then dried with Na2SO4, and filtered through a cotton plug. Solvent was then removed in vacuo and the brown oil was washed with ether (2 x 40 mL) and hexanes (3 x 40 mL) and then dried again. Solvent was fully moved by freeze drying the product in liquid nitrogen. The dried residue resulted in a brown oil product 5,6-bis(2-(2-(2- methoxyethoxy)ethoxy)ethoxy)-1 H-benzo[d]imidazole (6.4 g, 41 % yield).1H NMR (400 MHz, CDCI3): δ 7.81 (s, 1H NCHN), 7.32 (s, 2H, ArH), 4.22 (t, J = 4.9 Hz, 4H, -CH2-), 3.84 (t, J = 4.9 Hz, 4H, -CH2-), 3.77-3.51 (m, 16H, -CH2-), 3.41 (s, 6H, -CH3).13C{1H} NMR (100 MHz, CDCI3): δ 146.87 (ArC), 139.99 (NCN), 132.29 (ArC), 101.90 (ArC), 72.07 (ArC), 70.80 (ArC), 70.80 (ArC), 70.53 (ArC), 69.95 (ArC), 69.60 (ArC), 59.03 (OCH3). ESI-MS, calculated (m / z) for H+[C2iH34N20s]: 443.24; found: 443.24. Example 2B. Synthesis of 1-benzyl-5,6-bis(2-(2-(2-methoxyethoxy)ethoxy)ethoxy)-1H- benzo[d]imidazole
[0099] 1 -benzyl-5,6-bis(2-(2-(2-methoxyethoxy)ethoxy)ethoxy)-1 H-benzo[d]imidazole (see structural formula in Table 1) was prepared as follows. 5,6-bis(2-(2-(2- methoxyethoxy)ethoxy)ethoxy)-1 H-benzo[d]imidazole (2.116 g, 4.782 mmol) was dissolved in 30 mL of acetonitrile with KOH (0.805 g, 14.3 mmol) and stirred at room temperature for 2 h. Benzyl chloride (0.550 mL, 4.78 mmol) was added to the reaction mixture and stirred 16 h. Acetonitrile was removed in vacuo and the product was dissolved in DCM and filtered through a silica plug with 9:1 DCM:MeOH followed by 8:2 DCM:MeOH. The residue was then freeze dried in liquid nitrogen to yield a brown oil that was 1-benzyl-5,6-bis(2-(2-(2- methoxyethoxy)ethoxy)ethoxy)-1 H-benzo[d]imidazole (2.181 g, 85.6 %).1H NMR (600 MHz, CDCI3): δ 77.81 (s, 1H NCHN), 7.36-7.29 (m, 4H, ArH), 7.17-7.14 (m, 2H, ArH), 6.78 (s, 1 H, ArH), 5.29 (s, 2H, Benzyl -CH2-), 4.19 (t, J = 5.1 Hz, 2H, -CH2-), 4.11 (t, J = 5.1 Hz, 2H, -CH2-), 3.89 (t, J = 5.0 Hz, 2H, -CH2-), 3.83 (t, J = 5.0 Hz, 2H, -CH2-), 3.76 (m, 2H, -CH2-), 3.71 (m, 2H, -CH2-), 3.69-3.62 (m, 8H, -CH2-), 3.56-3.52 (m, 4H, -CH2-), 3.37 (s, 3H, -CH3), 3.36 (s, 3H, -CH3)13C{1H} NMR (150 MHz, CDCI3): δ 142.3 (NCN), 138.5 (ArH), 135.7 (ArH), 129.2 (ArH), 128.4 (ArH), 127.14 (ArH), 105.7 (ArH), 96.9 (ArH), 72.1 (-CH2-), 70.9 (-CH2-), 70.8 (-CH2-), 70.7 (-CH2-), 69.9 (-CH2-), 69.5 (-CH2-), 59.2 (-CH2-), 49.0 (-CH2-) ESI-MS, calculated (m / z) for H+[C2IH34N2O8]: 533.29; found: 533.29.
[0100] Example 2C. Synthesis of 1-(4-azidobenzyl)-5,6-bis(2-(2-(2-methoxyethoxy)ethoxy)ethoxy)- 1 H-benzo[d]imidazole
[0101] 1-(4-azidobenzyl)-5,6-bis(2-(2-(2-methoxyethoxy)ethoxy)ethoxy)-1H- benzo[d]imidazole (see Table 1 for structural formula) was prepared as follows. 5,6-bis(2-(2- (2-methoxyethoxy)ethoxy)ethoxy)-1H-benzo[d]imidazole (0.515 g, 1.16 mmol) was dissolved in 15 mL of acetonitrile with KOH (0.196 g, 3.49 mmol) and stirred at room temperature for 1 h. 1-azido-4-(chloromethyl)benzene (0.195 mL, 1.16 mmol) was added to the reaction mixture and stirred 16 h. Acetonitrile was removed in vacuo and the product was dissolved in DCM and filtered through Celite®. The residue was then freeze dried in liquid nitrogen to yield a brown oil that was 1-(4-azidobenzyl)-5,6-bis(2-(2-(2-methoxyethoxy)- ethoxy)ethoxy)-1H-benzo[d]imidazole (0.597 g, 89.4 %).1H NMR (600 MHz, CDCI3) 67.79 (s), 7.32 (s), 7.14 (d), 6.99 (d), 6.77 (s), 5.26 (s), 4.19 (t), 4.11 (t), 3.89 (t), 3.84 (t), 3.75-3.63 (m), 3.37 (s), 3.36 (s). ESI-MS, calculated (m / z) for H+[C28H39N5O8]: 574.29; found: 574.29.
[0102] Example 2D. General Synthesis for 4-methylhalide-ethylbenzoates and aryl linked benzimidazole
[0103] The 4-methylhalide-ethylbenzoates were prepared according to a literature procedure (J. Am. Chem. Soc. 2000, 122, 31 , 7518-7527). Aryl linked benzimidazole was prepared according to literature procedure (Organometallics 2014, 33, 22, 6544-6549).
[0104] Example 3. General Synthesis of NHC salts
[0105] 1 equivalent of aryl linked benzimidazole and 2.1 equivalent of benzyl halide were dissolved in acetonitrile and heated at 80°C overnight. The resulting solution was centrifuged and washed with 3 x 10 mL acetonitrile to afford off-white powder.
[0106] Example 3A. Synthesis of 1 ,1’-(diethylbenzoate)-3,3’-(1 ,2-xylylene)dibenzimidazolium dichloride
[0107] 1 ,1’-(diethylbenzoate)-3,3’-(1 ,2-xylylene)dibenzimidazolium dichloride a,a'-Bis(benzimidazol-1-yl)-o-xylene (500 mg, 1.48mmol) and ethyl (4- chloromethyl)benzoate (615 mg, 3.10 mmol) afforded the title compound in 69% yield (748 mg).1H NMR (DMSO-de, 400 MHz): δ 10.37 (s, 2H, NCHN), 8.10 - 8.06 (m, 2H), 7.99 - 7.91 (m, 6H), 7.72 - 7.61 (m, 8H), 7.45 (dd,3J = 3.4 Hz, 5.6 Hz, 2H), 7.27 (dd,3J = 3.4 Hz, 5.6 Hz, 2H), 4.30 (q,3J = 7.1 Hz, 4H, OCW2), 1.30 (t,3J = 7.1 Hz, 6H, CW3).13C{1H} NMR (DMSO-de, 400 MHz): δ 165.2 (C=O), 143.5 (NCN), 139.1 , 132.2, 131.4, 131.0, 130.1 , 129.6, 129.4, 128.8, 128.5, 127.0, 126.8, 114.3, 113.9, 60.9 (OCH2), 49.6 (CH2), 47.7 (CH2), 14.1 (CH3).
[0108] Example 3B. Synthesis of 1 ,1’-(diethylbenzoate)-3,3’-(1 ,2-xylylene)dibenzimidazolium dibromide
[0109] 1 ,1’-(diethylbenzoate)-3,3’-(1 ,2-xylylene)dibenzimidazolium dibromide a,a'-Bis(benzimidazol-1-yl)-o-xylene (500 mg, 1.48mmol) and ethyl (4- bromomethyl)benzoate(616 mg, 3.10 mmol) afforded the title compound in 66% yield (803 mg).1H NMR (DMSO-de, 400 MHz): δ 10.11 (s, 2H, NCHN), 8.04 - 7.92 (m, 8H), 7.73 - 7.63 (m, 8H), 7.46 (dd,3J = 3.4 Hz, 5.6 Hz, 2H), 7.29 (dd,3J = 3.4 Hz, 5.6 Hz, 2H), 6.15 (s, 4H, CH2), 5.95 (s, 4H, CH2), 4.30 (q,3J = 7.1 Hz, 4H, OCH2), 1.30 (t,3J = 7.1 Hz, 6H, CH3).13C{1H} NMR (DMSO-de, 400 MHz): δ 165.2 (C=O), 143.3 (NCN), 139.0, 132.0, 131.4, 131.0, 130.7, 129.6, 129.4, 128.8, 128.5, 127.0, 126.9, 114.3, 114.0, 60.9 (OCH2), 49.7 (CH2), 47.8 (CH2), 14.1 (CH3).
[0110] 3C. Synthesis of 1 ,1 (diethylbenzoate)-3,3’-(1 ,8- dimethylnaphthalene)dibenzimidazolium dichloride
[0111] 1 ,1’-(diethylbenzoate)-3,3’-(1 ,8-dimethylnaphthalene)dibenzimidazolium dichloride a,a'-Bis(benzimidazol-1-yl)-(1,8-naphthalene) (200 mg, 0.52 mmol) and ethyl (4- chloromethyl)benzoate (217 mg, 1.09 mmol) afforded the title compound in 56% yield (218 mg).
[0112] 1H NMR (DMSO-de, 400 MHz): δ 10.21 (s, 2H, NCHN), 8.10 (d,3J = 8.0 Hz, 2H), 8.02 - 7.94 (m, 8H), 7.72 - 7.60 (m, 8H), 7.53 (t,3J = 7.8 Hz, 2H), 7.07 (d,3J = 7.2 Hz, 2H), 6.75 (s, 4H, CH2), 5.99 (s, 4H, CH2), 4.30 (q,3J = 7.1 Hz, 4H, OCH2), 1.29 (t,3J = 7.1 Hz, 6H, CH3).13C{1H} NMR (DMSO-de, 400 MHz): δ 165.2 (C=O), 143.5 (NCN), 139.2, 135.5, 131.6, 131.2, 130.1 , 129.8, 129.6, 128.5, 127.3, 127.1 , 127.0, 125.8, 114.4, 114.1 , 60.9 (OCH2), 51.0 (CH2), 49.7 (CH2), 14.1 (CH3).
[0113] 3D Synthesis of 1 ,1’-(diethylbenzoate)-3,3’-(1,8- dimethylnaphthalene)dibenzimidazolium dibromide
[0114] 1 ,1’-(diethylbenzoate)-3,3’-(1 ,8-dimethylnaphthalene)dibenzimidazolium dibromide a,a'-Bis(benzimidazol-1-yl)-(7, 8-naphthalene) (300 mg, 0.77 mmol) and ethyl (4- bromomethyl)benzoate (380mg, 1.62 mmol) afforded the title compound in 55% yield (371.5 mg).1H NMR (DMSO-d6, 500 MHz): δ 9.74 (s, 2H), 8.05 (d, 4H), 7.89 (d, 2H), 7.61 (d, 4H), 7.24 (d, 2H), 6.62 (s, 4H), 5.91 (s, 4H), 4.36 (q, 4H), 1.38 (t, 6H).
[0115] Synthesis of Dimethylphenyl linked-diazidobenzyl NHC-X salt
[0116] Dimethylphenyl linked-diazidobenzyl NHC-X salt
[0117] 1 ,1’-(di-4-azidobenzyl)-3,3’-(1 ,2-xylylene)dibenzimidazolium dichloride was synthesized following an adapted literature procedure (see Yi, H., et al., Chemical Science 2021 , 72 (31), 10436-10440. DOI: 10.1039 / d1sc03076k). 1 ,2-bis((1H-benzo[d]imidazol-1- yl)methyl)benzene (1.0 mmol, 1.0 eq.) and 1-azido-4-(chloromethyl)benzene (369 mg, 2.2 mmol, 2.2 eq.) were suspended in acetonitrile (10 mL) and stirred for 3 d at 80 °C. After cooling to room temperature, the solvent was removed in vacuo, the crude product was washed with EtOAc (3x 25 mL) and dried in vacuo to afford pure product Dimethylphenyl linked-diazidobenzyl NHC-X salt (559 mg, 0.83 mmol, 83 %) as a colourless solid. C36H30CI2N10, MW: 673.6060 g / mol.1H-NMR (400 MHz, CDCI3): δ = 11.31 (s, 2H), 8.23 (d, J = 7.6 Hz, 2H), 7.76 - 7.04 (m, 18H), 6.64 (s, 4H), 5.82 (s, 4H).
[0118] Example 3K. Synthesis of 1-(4-azidobenzyl)-3-((8-((3-(4-azidobenzyl)-1H-benzodimidazol-3- ium-1-yl)methyl)naphthalen-1-yl)methyl)-1 H-benzodimidazolium dichloride
[0119] 1 -(4-azidobenzyl)-3-((8-((3-(4-azidobenzyl)-1 H-benzodimidazol-3-ium-1 - yl)methyl)naphthalen-1 -yl)methyl)-1 H-benzodimidazolium dichloride a,a,-Bis(benzimidazol-1-yl)-(1,8-naphthalene) (300 mg, 0.77 mmol) and 1-azido-4- (chloromethyl)benzene (283 mg, 1.694 mmol, 2.2 eq.) (380mg, 1.62 mmol) afforded the title compound in 63% yield.1H NMR: 5.78 (s, 4H, CH2), 7.04 (d, 6H), 7.25 (s, 4H, CH2), 7.36- 7.93 (m, 16H), 11.02 (s, 2H, NC / - / N).13C NMR 48.35, 49.28, 71.14, 129.41, 129.43, 137.71 , 142.68, 162.32, 187.40.
[0120] Example 4. Synthesis of NHC salts with triethylene glycol monomethyl ether backbone groups In this example, syntheses of NHC salt precursors that include triethyleneglycol monomethyl ether backbones. These backbone groups impart water solubility to the resulting clusters made with these NHCs.
[0121] Example 4A. Synthesis of triethyleneglycol monomethyl ether backbone NHC-halide2 salt The monoalkylated product (see C. above) was then dissolved in minimum acetonitrile and 0.5 equivalents of the halide-linker- halide species was added to the solution. The mixture was heated at 80 °C overnight, then solvent was removed in vacuo. The NHC- halide 2 salt was dissolved in DCM and then purified by column chromatography using an eluent system of DCM:MeOH (see Fig. 1).
[0122] Example 4B. Synthesis of 1 ,1'-(1 ,2-phenylenebis(methylene))bis(3-benzyl-5,6-bis(2-(2-(2- methoxyethoxy)ethoxy)ethoxy)-1 H-benzo[d]imidazol-3-ium) chloride
[0123] 1 , 1'-(1 ,2-phenylenebis(methylene))bis(3-benzyl-5,6-bis(2-(2-(2- methoxyethoxy)ethoxy)ethoxy)-1 H-benzo[d]imidazol-3-ium) chloride (see Table 1 for structural formula) was prepared as follows. 1-benzyl-5,6-bis(2-(2-(2- methoxyethoxy)ethoxy)ethoxy)-1 H-benzo[d]imidazole (0.5475 g, 1.028 mmol) (see structural formula in Table 1) and 1 ,2-bis(chloromethyl) benzene (0.0900 g, 0.514 mmol) were dissolved in 3.5 mL of acetonitrile. The mixture was heated at 80 °C for 21 h, then solvent was removed in vacuo. The NHC-X2 salt was dissolved in DCM and then purified by column chromatography using an 8:2 DCM:MeOH solvent system. Fractions containing the product were combined and dried in vacuo to yield the product (0.278 g, 44 %).1H NMR (400 MHz, CDCI3): δ 10.40 (s, 2H, NCHN), 8.09 (s, 2H, ArH), 7.35 (m, 12H, ArH), 7.04 (m, 2H, ArH), 6.92 (s, 2H, ArH), 6.47 (s, 4H, CH2), 5.67 (s, 4H, CH2) 4.40 (m, 4H, OCH2), 4.11 (m, 4H, OCH2), 3.90 (m, 4H, OCH2), 3.84 (m, 4H, OCH2), 3.71 (m, 8H, OCH2), 3.63 (m, 16H, OCH2), 3.53 (m, 8H, OCH2), 3.47 (m, 4H, OCH2), 3.36 (s, OCH3, 12H). methanol present slightly adds to integration of multiplet at 3.53 ppm.13C{1H} NMR (100 MHz, CDCI3): δ 151.12 (ArC), 150.22 (ArC), 139.91 (NCN), 132.99 (ArC), 132.40 (ArC), 130.06 (ArC), 129.56 (ArC), 129.35 (ArC), 129.26 (ArC), 128.01 (ArC), 127.17 (ArC), 124.89 (ArC), 98.33 (ArC), 97.59 (ArC), 72.09 (OCH2), 72.06 (OCH2), 71.01 (OCH2), 70.83 (OCH2), 70.81 (OCH2), 70.78 (OCH2), 70.65 (OCH2), 70.64 (OCH2), 70.02 (OCH2), 70.00 (OCH2), 59.16 (OCH3), 51.64 (CH2), 49.33 (CH2). ESI-MS, calculated (m / z) for [C64H88CIN4O16]+: 1203.59 ; found: 1203.59. ESI-MS, calculated (m / z) for [C64H88CIN4O16]2+584.31 ; found: 584.31.
[0124] Example 4C. Synthesis of 1 ,1'-(1,2-phenylenebis(methylene))bis(3-benzyl-5,6-bis(2-(2-(2- methoxyethoxy)ethoxy)ethoxy)-1 H-benzo[d]imidazol-3-ium) bromide
[0125] 1 , 1 '-(1 ,2-phenylenebis(methylene))bis(3-benzyl-5,6-bis(2-(2-(2- methoxyethoxy)ethoxy)ethoxy)-1 H-benzo[d]imidazol-3-ium) bromide (see Table 1 for structural formula) was prepared as follows. 1-benzyl-5,6-bis(2-(2-(2- methoxyethoxy)ethoxy)ethoxy)-1 H-benzo[d]imidazole (0.5475 g, 1.028 mmol)(see Table 1) and 1 ,2-bis(bromomethyl)benzene (0.1357 g, 0.5141 mmol) were dissolved in 4 mL of acetonitrile. The mixture was heated at 80 °C for 21 h, then solvent was removed in vacuo. The NHC-X2salt was dissolved in DCM and then purified by column chromatography using a 9:1 DCM:MeOH solvent system. Fractions containing the product were combined and dried in vacuo to yield the product (0.5005 g, 73 %).1H NMR (400 MHz, CDCI3): δ 10.18 (s, 2H, NCHN), 8.04 (s, 2H, ArH), 7.39 (m, 12H, ArH), 7.14 (s, 2H, ArH), 6.97 (d, 2H, ArH), 6.50 (s, 4H, CH2), 5.80 (s, 4H, CH2), 4.44 (m, 4H, OCH2), 4.22 (m, 4H, OCH2), 3.91 (m, 8H, OCH2), 3.77 (m, 8H, OCH2), 3.67 (m, 16H, OCH2), 3.57 (m, 8H, OCH2), 3.39 - 3.38 (two s, 12H, OCH3).13C{1H} NMR (100 MHz, CDCI3): δ 150.60 (ArH), 149.88 (ArH), 139.17 (NCN), 132.92 (ArH), 131.99 (ArH), 129.65 (ArH), 129.31 (ArH), 129.10 (ArH), 128.33 (ArH), 128.03 (ArH), 126.68 (ArH), 124.81 (ArH), 98.05 (ArH), 97.36 (ArH), 71.83 (2 OCH2), 70.77 (OCH2), 70.57 (OCH2), 70.54 (OCH2), 70.50 (OCH2), 70.38 (OCH2), 70.37 (OCH2), 69.97 (OCH2), 69.74 (OCH2), 69.35 (OCH2), 69.24 (OCH2), 58.92 (OCH3), 58.90 (OCH3), 51.43 (CH2), 49.23 (CH2). ESI-MS, calculated (m / z) for [C64H88CIN4O16]+: 1247.53; found: 1247.54. Elemental Analysis, calculated % for C64H38N4O16Br2: C, 57.83; H, 6.67 ; N, 4.22; found: C, 55.90; H, 5.88; N, 4.49.
[0126] Example 4D. Synthesis of 1 ,1'-(naphthalene-1 ,8-diylbis(methylene))bis(3-benzyl-5,6-bis(2- (2-(2-methoxyethoxy)ethoxy)ethoxy)-1H-benzo[d]imidazol-3-ium) bromide
[0127] 1 , 1 '-(naphthalene-1 ,8-diylbis(methylene))bis(3-benzyl-5,6-bis(2-(2-(2- methoxyethoxy)ethoxy)ethoxy)-1 H-benzo[d]imidazol-3-ium) bromide (structural formula in Table 1) was prepared as follows. 1-benzyl-5,6-bis(2-(2-(2-methoxyethoxy)ethoxy)ethoxy)- 1 H-benzo[d]imidazole (1.095 g, 2.056 mmol)(see Table 1) and 1 ,8- bis(bromomethyl)naphthalene (0.323 g, 1.03 mmol) were dissolved in 7 mL of acetonitrile. The mixture was heated at 80 °C for 21 h, then solvent was removed in vacuo. The NHC-X2salt was dissolved in DCM and then purified by column chromatography using first a 9:1 DCM:MeOH solvent system to elute the first band, followed by an 8:2 DCM:MeOH solvent system to elute the product. Fractions containing the product were combined and dried in vacuo to yield the product (0.9915 g, 70 %).
[0128] 1H NMR (400 MHz, CDCI3): δ 10.14 (s, 2H, NCHN), 8.08 (s, 2H, ArH), 7.90 (d, 2H, ArH), 7.55 - 7.34 (m, 16H, ArH, CH2), 7.22 (s, 2H, ArH), 6.53 (d, 2H, ArH), 5.81 (s, 4H, CH2), 4.41 (m, 4H, OCH2), 4.24 (m, 4H, OCH2), 3.91 (m, 8H, OCH2), 3.80 (m, 4 H, OCH2), 3.72 (m, 8H, OCH2), 3.64 (m, 12 H, OCH2), 3.53 (m, 8H, OCH2), 3.36 & 3.35 (s, 12H, OCH3).
[0129] 13C{1H} NMR (100 MHz, CDCI3): δ 150.53 (ArH), 149.78 (ArH), 139.36 (NCHN), 135.98 (ArH), 132.91 (ArH), 130.65 (ArH), 130.50 (ArH), 129.77 (ArH), 129.28 (ArH), 129.07 (ArH), 127.98 (ArH), 127.93 (ArH), 126.92 (ArH), 125.47 (ArH), 124.83 (ArH), 124.76 (ArH), 98.27 (ArH), 97.32 (ArH), 71.74 (OCH2), 71.71 (OCH2), 70.77 (OCH2), 70.51 (OCH2), 70.47 (OCH2), 70.41 (OCH2), 70.31 (OCH2), 70.28 (OCH2), 69.81 (OCH2), 69.80 (OCH2), 69.34 (OCH2), 69.16 (OCH2), 58.83 (OCH3), 58.81 (OCH3), 52.16 (CH2), 51.26 (CH2). ESI-MS, calculated (m / z) for [C64H88CIN4O16]+: 1297.55; found: 1297.55. Elemental Analysis, calculated % for C68H90N4O16Br2: C, 59.22; H, 6.58 ; N, 4.06; found: C, 57.72; H, 6.17; N, 4.32.
[0130] Example 4E. Synthesis of 1 ,1'-(naphthalene-1 ,8-diylbis(methylene))bis(3-(4-azidobenzyl)- 5,6-bis(2-(2-(2-methoxyethoxy)ethoxy)ethoxy)-1 H-benzo[d]imidazol-3-ium)bromide 1 ,1'-(naphthalene-1,8-diylbis(methylene))bis(3-(4-azidobenzyl)-5,6-bis(2-(2-(2- methoxyethoxy)ethoxy)ethoxy)-1 H-benzo[d]imidazol-3-ium)bromide (see structural formula in Table 1) was prepared as follows. 1-(4-azidobenzyl)-5,6-bis(2-(2-(2- methoxyethoxy)ethoxy)ethoxy)-1 H-benzo[d]imidazole (0.859 g, 1.50 mmol)(see Table 1) and 1 ,8-bis(bromomethyl)naphthalene (0.2351 g, 0.749 mmol) were dissolved in 10 mL of acetonitrile. The mixture was stirred at 80 °C for 24 h, then solvent was removed in vacuo. The NHC-X2salt was dissolved in DCM and then purified by column chromatography using a solvent system of 9:1 DCM:MeOH. Fractions containing the product were combined and dried in vacuo to yield the product (0.7093 g, 65 %).1H NMR (300 MHz, CDCI3): 10.16 (s, 2H), 7.98 (s, 2H), 7.90 (d, 2H), 7.41 - 7.35 (m, 6H), 7.08 - 7.02 (m, 10H), 6.73 (d, 2H), 5.61 (s, 4H), 4.37 (m, 4H), 4.17 (m, 4H), 3.86 (m, 8H), 3.75 - 3.49 (m, 32H), 3.35, 3.34 (two singlets, 12H).
[0131] Example 4F. Synthesis of 1,1'-(1,2-phenylenebis(methylene))bis(3-(4-azidobenzyl)-5,6-bis(2- (2-(2-methoxyethoxy)ethoxy)ethoxy)-1H-benzo[d]imidazol-3-ium) bromide
[0132] 1 , 1'-(1 ,2-phenylenebis(methylene))bis(3-(4-azidobenzyl)-5,6-bis(2-(2-(2- methoxyethoxy)ethoxy)ethoxy)-1 H-benzo[d]imidazol-3-ium) bromide (see Table 1for structural formula) was prepared as follows. 1-(4-azidobenzyl)-5,6-bis(2-(2-(2- methoxyethoxy)ethoxy)ethoxy)-1 H-benzo[d]imidazole (0.596 g, 1.04 mmol)(see Table 1) and 1 ,2-bis(bromomethyl)benzene (0.137 g, 0.519 mmol) were dissolved in 10 mL of acetonitrile. The mixture was stirred at rt for 24 h, then 40 °C for 16 h, and then 50 °C for 24 h, and then solvent was removed in vacuo. The NHC-X2salt was dissolved in DCM and then purified by column chromatography using a solvent system that went from 9:1 to 5:1 to 3:1 DCM:MeOH. Fractions containing the product were combined and dried in vacuo to yield the product (0.2847 g, 39 %).1H NMR (400 MHz, CDCI3) 5 10.22 (s), 8.06 (s), 7.42-7.36 (m), 7.09 - 6.96 (m), 6.45 (s), 5.64 (s), 4.42 (t), 4.16 (t), 3.93 - 3.84 (m), 3.75-3.60 (m), 3.55-3.50 (m), 3.35 (s). ESI-MS, calculated (m / z) for [C64H36BrN10O16]+: 1329.54; found: 1329.55. Example 5. Synthesis of gold complexes
[0133] Example 5A. Synthesis of NHC-(AuX)2gold complexes
[0134] As used herein, the term “DMS” refers to dimethyl sulphide. DMS-Au-CI was synthesized according to published procedure (Dalton Trans., 2018, 47, 3880).
[0135] Example 5B. Benzyl wingtip Naphthyl linked TEG-Me-backbone NHC(AuBr)2
[0136] Naphthyl linked NHC(AuBr)2 (see Table 2 for structural formula) was prepared as follows. 1 ,1'-(naphthalene-1 ,8-diylbis(methylene))bis(3-benzyl-5,6-bis(2-(2-(2- methoxyethoxy)ethoxy)ethoxy)-1 H-benzo[d]imidazol-3-ium) bromide (0.2479 g, 0.18 mmol) was stirred with CI-Au-(SMe2) (0.106 g, 0.36 mmol) in 4 mL of acetone for 1 h. K2CO3(0.15 g, 1.1 mmol) was added and the reaction mixture was heated to 60 °C for 2 h. Solvent was removed in vacuo and the complex was pushed through a silica plug with 9:1 DCM:MeOH. Solvent was removed in vacuo to yield 0.27 g of product at 85 % yield.1H NMR (400 MHz, CD2CI2): δ 7.94 (d, 2H, J = 7.7 Hz, ArH), 7.5 - 7.32 (m, 12H, ArH), 6.97 - 6.92 (d and s, d J = 7.4 Hz, 4 H, ArH), 6.56 (s, 2H, ArH), 6.50 (s, 4H, CH2), 5.76 (s, 4H, CH2), 4.08 (m, 4H, OCH2), 3.91 (m, 4H, OCH2), 3.79 (m, 4H, OCH2), 3.72 - 3.43 (m, 36H, OCH2), 3.32 & 3.28 (s, 12H, OCH3).13C{1H} NMR (100 MHz, CD2CI2): δ 181.42 (NCN), 148.88 (ArC), 148.47 (ArC), 136.21 (ArC), 135.36 (ArC), 130.98 (ArC), 130.79 (ArC), 130.73 (ArC), 129.35 (ArC), 128.76 (ArC), 127.91 (ArC), 127.62 (ArC), 127.53 (ArC), 127.42 (ArC), 125.98 (ArC), 98.38 (ArC), 97.53 (ArC), 72.24 (OCH2), 72.21 (OCH2), 71.09 (OCH2), 70.93 (OCH2), 70.83 (OCH2), 70.77 (OCH2), 70.72 (OCH2), 70.66 (OCH2), 70.03 (OCH2), 69.85 (OCH2), 69.76 (OCH2), 69.52 (OCH2), 58.96 (OCH3), 58.94 (OCH3), 54.03 (CH2), 53.20 (CH2). ESI-MS, calculated (m / z) for [ C68H88Au2BrN4O16]+: 1689.46 ; found: 1689.49. Elemental Analysis, calculated % for C68H88N4O16Au2Br2: C, 46.11 ; H, 5.01; N, 3.16; found: C, 46.58; H, 5.07; N, 3.08.
[0137] Example 5C. Synthesis of Benzyl-wingtip orthoxylyl-linker TEG-Me-backbone NHC(AuBr)2
[0138] Ortho-xylyl linked 1 ,1'-(1 ,2-phenylenebis(methylene))bis(3-benzyl-5,6-bis(2-(2-(2- methoxyethoxy)ethoxy)ethoxy)-1 H-benzo[d]imidazol-3-ium) bromide (0.25 g, 0.19 mmol) was stirred with CI-Au-(SMe2) (0.111 g, 0.38 mmol) in 6 mL of acetone for 1 h. K2CO3(0.156 g, 1.1 mmol) was added and the reaction mixture was heated to 60 °C for 2 h. Solvent was removed in vacuo and the complex was pushed through a silica plug with 9:1 DCM:MeOH. Solvent was removed in vacuo to yield 0.305 g of product at 94 % yield.1H NMR (400 MHz, CD2CI2): δ 7.41 - 7.25 (m. 12 H, ArH), 6.98 (m, 2H, ArH), 6.93 (s, 2H, ArH), 6.88 (s, 2H, ArH), 5.84 (s, 4H, CH2), 5.71 (s, 4H, CH2), 4.10 (m, 8H, OCH2), 3.80 (m, 8H, OCH2), 3.70 - 3.52 (m, 26H, OCH2), 3.49 (m, 8H, OCH2), 3.32 & 3.30 (s, 12H, OCH3).13C{1H} NMR (100 MHz, CD2CI2): δ 181.27 (NCN), 148.93 (ArC), 148.45 (ArC), 135.34 (ArC), 133.36 (ArC), 129.34 (ArC), 129.28 (ArC), 128.75 (ArC), 128.34 (ArC), 128.25 (ArC), 127.65 (ArC), 127.35 (ArC), 98.44 (ArC), 97.46 (ArC), 72.22 (2 OCH2), 71.07 (OCH2), 71.00 (OCH2), 70.81 (OCH2), 70.71 (OCH2), 70.69 (OCH2), 70.02 (OCH2), 69.97 (OCH2), 69.75 (OCH2), 69.67 (OCH2), 58.97 (2 OCH3), 53.15 (CH2), 50.64 (CH2). ESI-MS, calculated (m / z) for [C64H86Au2BrN4O16]+: 1639.45; found: 1639.46. Elemental Analysis, calculated % for C64H86N4O16Au2Br2: C, 44.66; H, 5.04; N, 3.26; found: C, 44.30; H, 4.84; N, 3.21.
[0139] Example 5D. Synthesis of Benzyl-wingtip ortho-xylyl-linked TEG-Me-backbone NHC(AuCI)2Ortho-xylyl linked 1 ,1'-(1 ,2-phenylenebis(methylene))bis(3-benzyl-5,6-bis(2-(2-(2- methoxyethoxy)ethoxy)ethoxy)-1 H-benzo[d]imidazol-3-ium) chloride (0.1731 g, 0.15 mmol) was stirred with CI-Au-(SMe2) (0.0872 g, 0.30 mmol) in 10 mL of acetone for 1 h. K2CO3(0.123 g, 0.89 mmol) was added and the reaction mixture was heated to 60 °C for 2 h. Solvent was removed in vacuo and the complex was pushed through a silica plug with 9:1 DCM:MeOH. Solvent was removed in vacuo to yield 0.206 g of product at 85 % yield.1H NMR (400 MHz, CD2CI2): δ 7.40 - 7.25 (m, 12 H, ArH), 6.95 - 6.85 (m, 6 H, ArH), 5.85 (s, 4H, CH2), 5.71 (s, 4H, CH2), 4.1 (m, 8 H, OCH2), 3.8 (m, 8 H, OCH2), 3.67 - 3.55 (m, 24 H, OCH2), 3.48 (m, 8 H, OCH2), 3.32 & 3.30 (s, 12 H, OCH3).13C{1H} NMR (100 MHz, CD2CI2): 5 178.25 (NCN), 149.04 (ArC), 148.47 (ArC), 135.36 (ArC), 133.25 (ArC), 129.37 (ArC), 129.21 (ArC), 128.78 (ArC), 128.35 (ArC), 127.97 (ArC), 127.65 (ArC), 127.40 (ArC), 98.47 (ArC), 97.35 (ArC), 72.27 (OCH2), 72.26 (OCH2), 71.13 (OCH2), 71.05 (OCH2), 70.88 (OCH2), 70.85 (OCH2), 70.77 (OCH2), 70.74 (OCH2), 70.09 (OCH2), 69.97 (OCH2), 69.82 (OCH2), 69.73 (OCH2), 59.00(OCH3), 58.98(OCH3), 53.23 (CH2), 50.62 (CH2). ESI-MS, calculated (m / z) for [C64H86Au2CIN4O16]+: 1595.51 ; found: 1595.52. Elemental Analysis, calculated % for C64H86N4O16Au2CI2: C, 47.10; H, 5.31 ; N, 3.43; found: C, 46.75; H, 5.25; N, 3.41.
[0140] Example 5E. Synthesis of 1 ,1’-di(4-ethylbenzoate)-3,3’-(1 ,2-xylylene)dibenzo[d]imidazol-2- ylidene digold(l) dichloride
[0141] 1 , 1 ’-di(4-ethylbenzoate)-3,3’-(1 ,2-xylylene)- dibenzo[d]imidazol-2-ylidene digold(l) dichloride 1 ,1’-(diethylbenzoate)-3,3’-(1 ,2-xylylene)dibenzimidazolium dichloride (100 mg, 0.136 mmol) and chloro(dimethylsulfidegold(l) (107 mg, 0.272 mmol) were dissolved in 10 mL acetone in a 15 mL pressure tube, and stirred at room temperature for 1 hour. Then, K2CO3(38 mg, 0.272 mmol) was added and the reaction was stirred at 60 °C in the dark for 2 hours at which point a white solid precipitated from solution. The resulting mixture was filtered and the solid was collected and suspended in 10 mL of DCM and washed with 10 mL of water in a separatory funnel. The organic phase was dried in vacuo to afford the title compound in 93% yield (142 mg).1H NMR (CDCI3, 300MHz): 8.03 (d, J = 7.7 Hz, 2H), 7.47-7.39 (m, 8H), 7.38-7.34 (m, 4H), 7.30-7.27 (m, 2H), 6.94-6.87 (m, 2H), 5.96 (s, 4H), 5.86 (s, 4H), 4.37 (q, J = 7.3 Hz, 4H), 1.38 (t, J = 7.1 Hz, 6H).
[0142] Example 5F. Synthesis of 1,T-di(4-ethylbenzoate)-3,3’-(1 ,2-xylylene)dibenzo[d]imidazol-2- ylidene digold(l) dibromide 1 ,1’-(diethylbenzoate)-3,3’-(1 ,2-xylylene)dibenzimidazolium dibromide (163 mg, 0.197 mmol) and chloro(dimethylsulfidegold(l) (116 mg, 0.394 mmol) were dissolved in 16 mL acetone in a 35 mL pressure tube, and stirred at room temperature for 1 hour. Then, K2CO3(54 mg, 0.394 mmol) was added and the reaction was stirred at 60 °C in the dark for 2 hours at which point a white solid precipitated from solution. The resulting mixture was filtered and the solid was collected and suspended in 10 mL of DCM and washed with 10 mL of water in a separatory funnel. The organic phase was dried in vacuo to afford the title compound in 98% yield (235 mg).1H NMR (CDCI3, 300MHz): 8.05 (d,3J = 8.3 Hz, 2H), 7.49- 7.41 (m, 8H), 7.40-7.35 (m, 4H), 7.32-7.29 (m, 2H), 6.98-6.91 (m, 2H), 5.98, (s, 4H), 5.88 (s, 4H), 4.38 (q,3J = 7.3 Hz, 4H), 1.39 (t,3J = 7.3 Hz, 6H).
[0143] Example 5G. Synthesis of 1 , 1 ’-di(4-ethylbenzoate)-3,3’-(1 ,8- dimethylnaphthelene)dibenzo[d]imidazol-2-ylidene digold(l) dichloride
[0144] 1 ,1’-(diethylbenzoate)-3,3’-(1 ,8-dimethylnaphthalene)dibenzimidazolium dichloride (100 mg, 0.127 mmol) and chloro(dimethylsulfidegold(l) (75 mg, 0.254 mmol) was dissolved in 10 mL acetone in a 15 mL pressure tube, and stirred at room temperature for 1 hour. Then, K2CO3(35 mg, 0.254 mmol) was added and the reaction was stirred at 60 °C in the dark for 2 hours. The resulting mixture was filtered and the filtrate was dried in vacuo to afford the title compound in 81% yield (121 mg).
[0145] Example 5H. Synthesis of 1 ,1’-di(4-ethylbenzoate)-3,3’-(1,8- dimethylnaphthelene)dibenzo[d]imidazol-2-ylidene digold(l) dibromide
[0146] 1 ,1’-(diethylbenzoate)-3,3’-(1 ,8-dimethylnaphthalene)dibenzimidazolium dibromide (80 mg, 0.091 mmol) and chloro(dimethylsulfidegold(l) (54 mg, 0.182 mmol) was dissolved in 8 mL acetone in a 15 mL pressure tube, and stirred at room temperature for 1 hour. Then, K2CO3(25 mg, 0.182 mmol) was added and the reaction was stirred at 60 °C in the dark for 2 hours. The resulting mixture was filtered and the filtrate was dried in vacuo to afford the title compound in 68% yield (87 mg).1H NMR (CDCI3, 300MHz): 8.04 (d, J = 8.20 Hz, 4H), 7.87 (d, J = 7.92 Hz, 2H), 7.47 (d, J = 8.1 Hz, 4H), 7.38-7.27 (m, 6H), 7.23-7.16 (m, 2H), 7.98-7.86 (m, 4H), 6.58 (s, 4H), 5.91 (s, 4H), 4.36 (q, J = 7.3 Hz, 4H), 1.37 (t, J = 7.2 Hz, 6H).
[0147] Example 5L General Synthesis Azidated NHC2-AU2-CI2 Complexes
[0148] Azidated gold complexes were synthesized following an adapted literature procedure (Yi, H. et al., Chem. Sci. (2021) 12, 10436-10440). The appropriate bis-NHC salt (101 mg, 0.15 mmol, 1.0 eq.) and K2CO3(124 mg, 0.90 mmol, 6.0 eq.) were suspended in acetone (50 mL) and stirred at room temperature for 30 min. Me2SAuCI (88 mg, 0.30 mmol, 2.0 eq.) was suspended in acetone (5 mL) and added dropwise to the mixture. After stirring at room temperature for 15 more minutes, the mixture was heated to 60 °C for 12 h. After cooling to room temperature, the solvent was removed in vacuo and the crude product was purified by flash column chromatography (Fuji Silysia Chromatorex PSQ60AB silica, 20:1 DCM / MeOH) to afford the pure complex product 5 (72 mg, 68 μmol, 45 %) as a colourless solid.
[0149] Example 5J. Synthesis of orthoxylyl-dibenzo-p-azido-[d]imidazol-2-ylidene digold(l) dichloride
[0150] 1 ,1’-(di-4-azidobenzyl)-3,3’-(1 ,2-xylylene)dibenzimidazolium dichloride was the NHC salt used in this synthesis (as above). Orthoxylyl-dibenzo-p-azido-[d]imidazol-2-ylidene digold(l) was isolated as a colourless solid (72 mg, 0.068 mmol, 45 %).1H NMR: 5.70 (s, 4H), 5.89 (s, 4H), 6.84 (m, 2H), 6.95 (d, 4H), 7.20 (m, 2H), 7.34 (m, 12H).
[0151] Example 5K. Synthesis of 1 ,2-napthylene-dibenzo-p-azido-[d]imidazol-2-ylidene digold(l) dichloride
[0152] NHC salt, 1-(4-azidobenzyl)-3-((8-((3-(4-azidobenzyl)-1 H-benzodimidazol-3-ium-1- yl)methyl)naphthalen-1-yl)methyl)-1H-benzodimidazolium dichloride, was used in this synthesis
[0153] According to the general procedure (Yi, H. et al. Chem. Sci. (2021) 12, 10436-10440). The 1 ,2-napthylene-dibenzo-p-azido-[d]imidazol-2-ylidene digold(l) dichloride complex was isolated as a colourless solid (154 mg, 0.14 mmol, 65%).1H NMR 4.09 (d, 2H), 4.41 (t, 2H), 4.46 (d, 2H), 6.80 (d, 4H), 7.05 (d, 4H), 7.14 (m, 6H), 7.23 (d, 2H), 7.43 (d, 4H).
[0154] Example 5L Synthesis of gold complex L(AuBr)2where L is (4-azidobenzyl-wingtip orthoxylyl-linker TEG-Me backbone) NHC
[0155] 1 , 1 '-(1 ,2-phenylenebis(methylene))bis(3-(4-azidobenzyl)-5,6-bis(2-(2-(2- methoxyethoxy)ethoxy)ethoxy)-1 H-benzo[d]imidazol-3-ium) bromide (0.285 g, 0.20 mmol) (see structural formula in Table 1 was stirred with CI-Au-(SMe2) (0.119 g, 0.40 mmol) in 10 mL of acetone for 1 h. K2CO3(0.167 g, 1.2 mmol) was added and the reaction mixture was heated to 60 °C for 1 h. Solvent was removed in vacuo and the complex was pushed through a silica plug with 8:2 DCM:MeOH. Solvent was removed in vacuo to yield 0.329 g of product at 90 % yield.1H NMR (700 MHz, CD2CI2): δ 7.40 (d, 4H), 7.31 (m, 2H), 7.02 (d, 2H), 7.0 - 6.8 (m, 6H), 5.82 (s, 4H), 5.68 (s, 4H), 4.15 - 4.05 (m, 8 H), 3.85 - 3.75 (m, 8H), 3.7 - 3.4 (m, 32H), 3.35 - 3.25 (two s, 12H).13C{1H} NMR (175 MHz, CD2CI2): δ 181.20, 148.97, 148.56, 140.62, 133.33, 132.03, 129.34, 129.27, 128.53, 128.19, 127.25, 119.91 , 98.33, 97.49, 72.23, 71.11 , 71.05, 70.85, 70.83, 70.74, 70.71 , 70.10, 69.96, 69.82, 69.69, 58.96, 52.53, 50.83. ESI-MS, calculated (m / z) for [C64H84Au2BrN10O16]+: 1721.46; found: 1721.47.
[0156] Example 6. Synthesis of Water-soluble Gold Nanoclusters
[0157] Example 6A. Synthesis of [AU13(L)5CI2]CI3where L is (benzyl-wingtip orthoxylyl-linker TEG- Me- backbone)NHC
[0158] The title NHC cluster (see Table 3) was prepared as follows. In a 250 mL round bottom flask, NHC(AuCI)2(0.100 g, 0.0613 mmol) was dissolved in 31.5 mL 99% pure dichloromethane (DCM) and 15.75 mL 97 % EtOH at 0 °C. NaBH4(4.64 mg, 0.123 mmol) was added all at once in 15.75 mL of EtOH. The reaction was stirred for 1 h, then was allowed to warm to room temperature and it was stirred for 18 h. Then, 20.1 pL of cone. HCI (4 equiv.) was added and the reaction mixture was stirred for a further 24 h. The solvent was removed in vacuo and the reaction mixture was dissolved in DCM and filtered through CELITE® plug. Then the product was purified by column chromatography with a solvent system of 5:1 DCM:MeOH. The fractions containing only AU13 were combined and dried to yield the cluster (0.0247 g, 31 % yield based on Au).1H NMR (700 MHz, CD2CI2): δ 7.50 - 7.30 (m, 3H), 7.19 (t, J = 7.8 Hz, 1 H), 7.14 (d, J = 16.1 Hz, 1 H), 7.00 (m, 2H), 6.85 - 6.45 (m, 11 H), 6.33 (t, J = 7.0 Hz, 1 H), 5.80 (s, 1 H), 5.56 (s, 1 H), 5.06 (d, J = 16.0 Hz), 4.61 (d, J = 14.7 Hz, 1 H), 4.39 (m, 2H), 4.00 (m, 2H), 3.87 (m, 2H), 3.8 - 3.4 (m, 43.4 H), 3.33, 3.30, 3.28, 3.27 (s, 12H). Spectra normalized to one NHC ligand on the surface of the cluster.13C{1H} NMR (175 MHz, CD2CI2): δ 206.86 (NCN), 205.86 (NCN), 148.72 (ArC), 148.19 (ArC), 147.74 (ArC), 147.61 (ArC), 137.35 (ArC), 134.67 (ArC), 133.78 (ArC), 132.43 (ArC), 131.12 (ArC), 129.54 (ArC), 129.44 (ArC), 129.30 (ArC), 129.09 (ArC), 129.07 (ArC), 128.71 (ArC), 128.49 (ArC), 128.20 (ArC), 127.76 (ArC), 127.55 (ArC), 127.45 (ArC), 127.33 (ArC), 125.89 (ArC), 99.68 (ArC), 99.36 (ArC), 99.25 (ArC), 98.27 (ArC), 72.29 (-OCH2-), 72.28 (- OCH2-), 72.24 (-OCH2-), 72.21 (-OCH2-), 71.26 (-OCH2-), 71.14 (-OCH2-), 71.06 (-OCH2-), 71.03 (-OCH2-), 70.93 (-OCH2-), 70.83 (-OCH2-), 70.81 (-OCH2-), 70.77 (-OCH2-), 70.75 (- OCH2-), 70.71 (-OCH2-), 70.66 (-OCH2-), 69.94 (-OCH2-), 69.81 (-OCH2-), 69.73 (-OCH2-), 69.58 (-OCH2-), 69.55 (-OCH2-), 69.43 (-OCH2-), 59.02 (CH3), 59.00 (CH3), 58.98 (CH3), 58.96 (CH3), 53.54 (wingtip CH2(under solvent peak)), 52.89 (wingtip CH2), 51.97 (xylyl CH2), 48.11 (xylyl CH2). ESI-MS, calculated (m / z) for [C32oH43oAU13CI2N2o08o]3+: 2821.1733; found: 2821.1487. UV-vis spectrum in DCM: High intensity sharp peak at 346 nm, absorbance plateau from 563 nm to 410 nm with a small broad absorbance band at 463 nm. Example 6B. Synthesis of [AU13(L)5Br2]Br3where L is (Benzyl-wingtip orthoxylyl-linker TEG-Me backbone)NHC
[0159] The title NHC cluster (see structural formula in Table 3) was prepared as follows. In a 250 mL round bottom flask, NHC(AuBr)2 (0.1525 g, 0.0887 mmol) was dissolved in 44.3 mL HPLC DCM and 22.15 mL 97 % EtOH at 0 °C. NaBH4(6.7 mg, 0.177 mmol) was added all at once in 12.15 mL of EtOH. The reaction was allowed to warm to room temperature after 1 h of stirring and stirred for 24 h. NaBr (0.091 g, 0.88 mmol) was then added to the reaction mixture and all was stirred 24 h. 14.4 pL of cone. HCI (2 equiv.) was added and the reaction mixture was stirred for 24 h. The solvent was then removed in vacuo and the reaction mixture filtered through Celite® in DCM. DCM was then removed in vacuo and the reaction mixture dissolved in EtOH. NaBr (0.091 g, 0.88 mmol) was added and the reaction mixture stirred 1 h. Solvent was then removed and the reaction mixture dissolved in DCM. Then the product was purified by column chromatography with a solvent system of 5:1 DCM:MeOH. The fractions containing only AU13were combined and dried to yield the cluster (0.0284 g, 24 % yield based on Au). ESI-MS, calculated (m / z) for [C320H430Au13Br2N20O80]3+: 2850.4720 ; found: 2850.4733.1H NMR (700 MHz, CD2CI2): δ 7.48 (d, J = 8.1 Hz, 1 H), 7.41 (s, 1 H), 7.32 (d, J = 15.7 Hz, 1 H), 7.19 (t, J = 7.9 Hz, 1 H), 7.13 (d, J = 16.4 Hz, 1 H), 7.05 - 6.95 (m, 2H), 6.9 - 6.5 (m, 11 H, 1 H), 6.32 (t, J = 7.4 Hz, 1 H), 5.73 (s, 1 H), 6.60 (s, 1 H), 5.10 (d, J = 16.1 Hz, 1 H), 4.70 (d, J = 14.5 Hz, 1 H), 4.45 (m, 2H, 1 H), 4.2 - 4.1 (m, 1 H), 4.05 (m, 1 H), 3.95 (m, 1 H), 3.87 (m, 2H), 3.8 - 3.4 (m, 44H), 3.33, 3.31 , 3.28, 3.27 (s, 12 H). Spectra normalized to one NHC ligand on the surface of the cluster.13C{1HJ NMR (151 MHz, CD2CI2): δ 206.41 (NCN), 205.49 (NCN), 148.61 (ArC), 148.12 (ArC), 147.66 (ArC), 147.59 (ArC), 137.51 (ArC), 134.60 (ArC), 133.76 (ArC), 132.44 (ArC), 131.31 (ArC), 129.59 (ArC), 129.41 (ArC), 129.35 (ArC), 129.05 (ArC), 128.66 (ArC), 128.52 (ArC), 128.29 (ArC), 127.81 (ArC), 127.57 (ArC), 127.48 (ArC), 127.26 (ArC), 125.94 (ArC), 99.85 (ArC), 99.52 (ArC), 99.46 (ArC), 98.54 (ArC), 72.31 (-OCH2-), 72.28 (-OCH2-), 72.25 (-OCH2-), 72.21 (-OCH2-), 71.24 (-OCH2-), 71.13 (-OCH2-), 71.04 (-OCH2-), 71.01 (-OCH2-), 70.92 (-OCH2-), 70.84 (- OCH2-), 70.81 (-OCH2-), 70.74 (-OCH2-), 70.72 (-OCH2-), 70.66 (-OCH2-), 69.98 (-OCH2-), 69.82 (-OCH2-), 69.72 (-OCH2-), 69.66 (-OCH2-), 69.59 (-OCH2-), 69.53 (-OCH2-), 69.45 (- OCH2-), 69.37, 59.04 (CH3), 59.02 (CH3), 59.00 (CH3), 58.98 (CH3), 53.91 (wingtip CH2under solvent peak), 53.81 (wingtip CH2under solvent peak), 51.95 (xylyl CH2), 48.22 (xylyl CH2). UV-vis spectrum in DCM: High intensity sharp peak at 348 nm, absorbance plateau from 550 nm to 420 nm with a small broad absorbance band at 465 nm.
[0160] Example 6C. Synthesis of [AU13(L)5Br2]Br3where L is (Benzyl-wingtip naphthyl-linker TEG- Me- backbone)NHC The title NHC cluster (see structural formula in see Table 3) was prepared as follows. In a 250 mL round bottom flask, NHC(AuBr)2(0.1346 g, 0.0760 mmol) was dissolved in 38 mL HPLC DCM and 19 mL 97 % EtOH at 0 °C. NaBH4(5.75 mg, 0.152 mmol) was added all at once in 19 mL of EtOH. The reaction was allowed to warm to room temperature after 1 h of stirring and stirred for 24 h. NaBr (0.078 g, 0.76 mmol) was then added to the reaction mixture and all was stirred 24 h. 12.35 pL of cone. HCI (2 equiv.) was added and the reaction mixture was stirred for 24 h. The solvent was then removed in vacuo and the reaction mixture filtered through Celite® in DCM. DCM was then removed in vacuo and the reaction mixture dissolved in EtOH. NaBr (0.078 g, 0.76 mmol) was added and the reaction mixture stirred 1 h. Solvent was then removed and the reaction mixture dissolved in DCM. Then the product was purified by column chromatography with a solvent system of 5:1 DCM:MeOH. The fractions containing only AU13 were combined and dried to yield the cluster (0.0322 g, 30 % yield based on Au). ESI-MS, calculated (m / z) for [C340H440Au13Br2N20O80]3+: 2933.8312; found: 2933.8154.1H NMR (600 MHz, CD2CI2): δ 8.04 (d, J = 8.2 Hz, 2H) , 7.87 (d, J = 14.7 Hz, 2H), 7.35 (t, J = 7.6 Hz, 2H), 7.10 (d, J = 16.9 Hz, 2H), 6.73 (t, J = 7.6 Hz, 2H), 6.43 (d, J = 7.1 Hz, 2H), 5.62 (s, 2H), 4.30 (d, J = 15.1 Hz, 2H), 4.07 (s, 2H), 3.75 - 3.45 (m, 46 H), 3.32 & 3.29 (s, 12H), 3.21 (m, 2H), 2.89 (d, J = 16.4 Hz, 2H). Spectra normalized to one NHC ligand on the surface of the cluster.13C{1H} NMR (151 MHz, CD2CI2): 6205.04 (NCN), 147.65 (ArC), 147.60 (ArC), 136.06 (ArC), 135.81 (ArC), 134.03 (ArC), 132.56 (ArC), 130.71 (ArC), 129.27 (ArC), 129.02 (ArC), 128.27 (ArC), 127.45 (ArC), 126.91 (ArC), 126.78 (ArC), 97.91 (ArC), 96.53 (ArC), 72.30 (2 OCH2), 71.23 (OCH2), 71.19 (OCH2), 70.91 (OCH2), 70.83 (OCH2), 70.77 (OCH2), 70.77 (OCH2), 69.58 (OCH2), 69.37 (OCH2), 69.20 (OCH2), 68.93 (OCH2), 59.04 (-OCH3), 59.02(-OCH3), 57.23 (naphthyl CH2), 52.8 (under CD2CI2signal, wingtip CH2). UV-vis spectrum in DCM: High intensity sharp peak at 342 nm, small broad peaks at 436 nm and 476 nm, with absorbance beginning at 550 nm.
[0161] Example 6D. Synthesis of [AU13(L)5Br2]X3where L is (4-Azidobenzyl-wingtip orthoxylyl-linker )NHC
[0162] The title NHC cluster (see structural formula in Table 3) was synthesized following an adapted literature procedure (Yi, H. et al., Chem. Sci. (2021) 12, 10436-10440). To a solution of orthoxylyl-dibenzo-p-azido-[d]imidazol-2-ylidene digold(l) dichloride (50 μmol, 1.0 eq.) in DCM / EtOH (2:1 , 30 mL) was added a solution of NaBH4(100 μmol, 2.0 eq.) in EtOH (10 mL) at 0 °C and the mixture was stirred for 1 h. The mixture was allowed to warm up to room temperature and stirring was continued for 2 h. Concentrated HCI (9 μl, 100 μmol, 2.0 eq.) was added and the mixture was stirred for 1 h at room temperature. The solvent was removed in vacuo, and the residue was extracted with EtOH (5x 3 mL). The combined extraction solutions were filtered through CELITE®, the eluent was removed in vacuo and the remaining solid was purified by flash column chromatography (Fuji Silysia Chromatorex PSQ60AB silica, DCM / MeOH) to afford the AU13gold cluster (5.2 mg, 9 μmol, 18%) as a red solid, o-xylyl linked azide cluster: C180H140AU13CI5N50, MW: 5741.2030 g / mol. UV-Vis Peaks: 283 nm, 280 nm, 335 nm, 431 nm, 513 nm1H NMR: 5.60 (s), 5.71 (s), 6.29 (s), 6.46 (s), 6.67 (t), 7.20 (m), 7.37 (m), 7.51 (m), 7.57 (m), 7.68 (d), 7.82 (d), 7.97 (d), 8.10 (s). ESI-MS, calculated (m / z) for [C180H140Au13CI2N50]3+: 1877.25; found: 1877.24.
[0163] Example 6E. Synthesis of [AU13(bis-L)5CI2]CI3where L is (Azide-wingtip 1 ,8-napthyl- linker)NHC
[0164] The title bis-NHC protected AU13 gold cluster was synthesized following an adapted literature procedure (Yi, H. et al., Chem. Sci. (2021) 12, 10436-10440) as explained above in Example 6D, with 1 ,8-napthyl-dibenzo-p-azido-[d]imidazol-2-ylidene digold(l) dichloride. 1 ,8- napthyl linked azide cluster: C200H150Au13CI2N50, MW: 5881.83 g / mol. UV-Vis Peaks: 291 nm, 327 nm, 265 nm, 429 nm, 511 nm1H NMR: 3.36 (d), 3.52 (d), 3.69 (d), 4.65 (d), 6.35 (t), 6.83 (d), 7.05 (t), 7.19 (s), 7.26 (d), 7.90 (d), 8.05 ESI-MS, calculated (m / z) for [ C180H140AU13CI2N50]3+: 1960.61 ; found: 1961.59.
[0165] Example 6F. Synthesis of [AU13(NHC)5Br2]X3where L is (4-Azidobenzyl-wingtip naphthyl- linker TEG-Me backbone)NHC
[0166] The title NHC cluster (see Table 3) was prepared as follows. A 1 ,1'-(naphthalene-1 ,8- diylbis(methylene))bis(3-(4-azidobenzyl)-5,6-bis(2-(2-(2-methoxyethoxy)ethoxy)ethoxy)-1 H- benzo[d]imidazol-3-ium)bromide salt (0.3293 g, 0.2253 mmol) was stirred with CI-Au-(SMe2) (0.1375 g, 0.4668 mmol) in 10 mL of acetone for 1 h. K2CO3(0.193 g, 1.40 mmol) was added and the reaction mixture was heated to 60 °C for 3.5 h. Solvent was removed in vacuo and the complex was pushed through a silica plug with 10:1 DCM:MeOH. Solvent was removed in vacuo to yield 0.3328 g of product at 79 % yield. The product was carried forward without further purification.
[0167] In a 500 mL round-bottom flask, 0.210 g (0.12 mmol) of NHC(AuBr)2was dissolved in 270 mL of HPLC-grade dichloromethane (DCM) and 135 mL of 97% ethanol at 0 °C. Then, 8.57 mg (0.24 mmol) of sodium borohydride (NaBH4) was dissolved all at once in 135 mL of ethanol. The NaBH4solution in ethanol was added dropwise to the reaction mixture. The color of the reaction mixture gradually changed to dark red. The reaction was allowed to warm to room temperature after 1 hour of stirring, and then it was stirred for an additional 21 hours. Next, 19.8 μL (2 equivalents) of concentrated hydrochloric acid (HCI) was added, and the reaction mixture was stirred for 0.5 hours. The solvent was then removed under reduced pressure. The resulting cluster was purified by column chromatography using a solvent system that progressed from 19:1 to 9:1 DCM:MeOH. The fractions containing only AU13were combined and dried to yield the cluster (0.061 g, Yield: 6%). ESI-MS, calculated (m / z) for [C340H430AU13Br2N50O80]3+: 3070.5060 ; found: 3070.5. UV-vis spectrum in DCM: For AU13nanocluster, the absorption peaks were recorded at specific wavelengths of 340nm, 430 nm,468 nm, and 513 nm.
[0168] Example 6G. Synthesis of [AU13(L)5Br2]X3where L is (4-azidobenzyl-wingtip orthoxylyl-linker TEG-Me-backbone)NHC and X is a counterion
[0169] The title NHC gold cluster (see Table 3) was prepared as follows. In a 250 mL round bottom flask, NHC(AuBr)2(0.1645 g, 0.0912 mmol) was dissolved in 44 mL HPLC DCM and 22 mL 97 % EtOH at 0 °C. NaBH4(6.9 mg, 0.18 mmol) was added all at once in 22 mL of EtOH. The reaction was allowed to warm to room temperature after 1 .5 h of stirring and then stirred for 2 h. 15 pL of cone. HCI (2 equiv.) was added and the reaction mixture was stirred for 1 h. The solvent was then removed in vacuo. The cluster was purified by column chromatography using a solvent system that went from 9:1 to 5:1 to 4:1 to 3:1 DCM:MeOH. The fractions containing only AU13were combined and dried to yield the cluster (0.008 g, 9 % yield based on Au). ESI-MS, calculated (m / z) for [C320H420AU13Br2N50O80]3+: 2987.14; found: 2987.19. UV-vis spectrum in DCM: High intensity broad peak at 341 nm, absorbance plateau from 555 nm to 420 nm with a small broad absorbance band at 462 nm.
[0170] Example 6H. General Synthesis of [AU13(L)5X2]Y3, where L is an NHC with wingtip, linker, and backbone moieties as specified, and X is a monovalent ligand, and Y is a counterion as specified.
[0171] NHC2-AU2-X2was dissolved 2:1 CH2CI2:EtOH and cooled to 0C. NaBH4(2 eq.) in EtOH was sonicated and added dropwise and the solution was stirred at 0 for 1 hour, followed by 2 hours at room temperature. 2 eq. HCI was added, and the resulting red solution was stirred for 30 minutes at room temperature. The solvent was evaporated under reduced pressure. The product was dissolved in minimal amounts of CH2CI2and purified by column chromatography in 9:1 CH2CI2:MeOH to afford a pure product as bright red powder.
[0172] Example 6L Synthesis of [AU13(L)SCI2]Y3where L is (di-ethyl-benzoate-wingtip ortho-xylyl- linker)NHC, and Y is a counterion (e.g., Cl, Br, BF4, or PF6)
[0173] Referring to the general synthesis of Example 6H, 1 ,1’-di(4-ethylbenzoate)-3,3’-(1 >2- xylylene)dibenzo[d]imidazol-2-ylidene digold(l) dichloride (142 mg, 0.146 mmol) afforded the title compound in 6% yield based on Au (8 mg). ESI-MS, calculated (m / z) for [C210H190Au13CI2N20O20]3+: 1980.65; found: 1980.65. Example 6J. Synthesis of [AU13(L)5Br2]X3where L is (di-ethyl-benzoate-wingtip orthoxylyl- linker)NHC and X is a counterion (e.g., Cl, Br, BF4, or PFe)
[0174] Referring to the general synthesis of Example 6H, 1 ,1’-di(4-ethylbenzoate)-3,3’-(1 ,2- xylylene)dibenzo[d]imidazol-2-ylidene digold(l) dibromide (235 mg, 0.193 mmol) afforded the title compound in 12% yield based on Au (22.8 mg). ESI-MS, calculated (m / z) for [C210H190AU13Br2N20O20]3+: 2009.95; found: 2009.96.1H NMR (CD2CI2, 700 MHz): δ 7.9 (d,3J = 8.3 Hz, 5H), 7.55 (t,3J = 7.7 Hz, 5H), 7.44 (d,2J = 16.0 Hz, 5H, a-NCH2Ar), 7.37 - 7.32 (m, 10H, b- NCH2Ar), 7.28 -7.20 (m, 25H), 7.17 (t, 5H,2J = 7.7 Hz, backbone-CH), 7.07 - 7.02 (m, 10H), 7.00 (d,3J = 8.2 Hz, 5H), 6.95 (t,3J = 7.5 Hz, 5H), 6.87 - 6.74 (m, 25H, c-NCH2Ar, d-NCH2Ar), 6.72 (d,3J = 7.9 Hz, 5H), 6.56 (d,2J = 7.6 Hz, 5H, NCH2Ar), 6.34 (d,2J = 8.5 Hz, 5H, NCH2Ar), 6.00 (d,2J = 8.4 Hz, 5H, NCH2Ar), 5.68 (d,2J = 16.0 Hz, 5H, a-NCH2Ar), 5.07 (d,2J = 14.7 Hz, 5H, c-NCH2Ar), 4.80 (d,2J = 17.0 Hz, 5H, b-NCH2Ar), 4.26 - 4.07 (m, 20H, OCH2), 3.56 (d,2J = 13.8 Hz, 5H, d-NCH2Ar), 1.29 - 1.25 (m, 30H, CH3).13C{1H} NMR (CD2CI2, 700 MHz): δ 206.8 (NCN), 205.9 (NCN), 165.5 (C=O), 165.4 (C=O), 138.9, 137.8,
[0175] 137.1 , 135.4, 133.6, 133.0, 132.7, 132.1 , 131.5, 130.7, 130.2, 129.8, 129.7, 129.3, 129.1 ,
[0176] 127.2, 126.0, 125.9, 125.3, 125.3, 124.9, 115.9, 114.9, 113.8, 113.7, 61.4 (OCH2), 61.1 (OCH2), 53.5 (c-NCH2Ar), 53.0 (d-NCH2Ar), 52.4 (b-NCH2Ar), 49.0 (a-NCH2Ar), 14.4 (CH3). UV-Vis absorption spectrum in DCM: Local Maxima at 292 nm, 302 nm, 321 nm, 338 nm, 409 nm, 453 nm, 516 nm.
[0177] Example 6K. Synthesis of [AU13(L)5Br2]X3where L is (di-ethyl-benzoate-wingtip 1 ,8- dimethylnapthalene-linker)NHC where X is a counterion (e.g., Cl, Br, BF4, or PFe)
[0178] Referring to the general synthesis of Example 6H, 1 ,1’-di(4-ethylbenzoate)-3,3’-(1 ,8- dimethylnaphthelene)dibenzo[d]imidazol-2-ylidene digold(l) dichloride (87 mg, 0.062 mmol) afforded the title compound in 28% yield (19 mg). ESI-MS, calculated (m / z) for [C230H200AU13Br2N20O20]3+: 2093.31 ; found: 2093.32. UV-Vis absorption spectrum in MeOH: local maxima at 284 nm, 291 nm, 329 nm, 416 nm.
[0179] Example 6L. General procedure for the saponification of ethyl benzoate clusters [AU13(NHC)5Br2]X3(X=CI, Br, BF4, or PF6)
[0180] Cluster [AU13(NHC)5Br2]X3and 60 eq KOH was dissolved in a solution of 2:1 H2O:DMSO and heated for 2 hours at 90°C in the dark. The resulting solution was filtered through celite then the pH was adjusted to 1 using concentrated HCI to generate a red precipitate. The solution was filtered through celite and the remaining red powder was washed with pH=1 water followed by Et2O and DCM. Finally, the red powder was washed out using MeOH and the solution was concentrated in vacuo to yield a red solid. This was dissolved in a small amount of ethanol and pipetted into a dialysis mesh which was sealed and stirred in absolute ethanol overnight. The remaining red solution in the dialysis mesh was then removed and concentrated in vacuo to yield a red powder.
[0181] Example 6M. Synthesis of [AU13(L)5Br2]X3where L is (di-benzoic acid-wingtip orthoxylyl- linker)NHC and X is a counterion (e.g., Cl, Br, BF4, or PF6)
[0182] Referring to the reaction of Example 6L, [AU13(L)5Br2]X3where L is (di-ethyl- benzoate-wingtip O-xylyl-linker)NHC (5.9 mg, 0.94 μmol) afforded the title compound in 66% yield (3.7 mg). ESI-MS, calculated (m / z) for [C190H150AU13Br2N20O20]3+: 1916.51 ; found: 1916.53.1H NMR (DMSO-d6, 700 MHz): δ 12.61 (br s, 10H, COOH), 7.87 (d, 5H,3J = 7.8 Hz), 7.57 (t, 5H,3J = 7.3 Hz), 7.37 -7.28 (m, 20H, a-NC / 72Ar), 7.19 - 7.11 (m, 20H, b- NCH2Ar), 7.10 - 7.07 (m, 10H), 7.02 (t, 5H,3J = 7.4 Hz), 6.95 - 6.82 (m, 35H), 6.72 (d, 5H,2J = 13.3 Hz, c-NCH2Ar), 6.66 (d, 5H,2J = 13.1 Hz, a-NCH2Ar), 6.33 (d, 5H,2J = 7.9 Hz), 6.17 (d, 5H,2J = 6.5 Hz), 5.99 (d, 5H,3J = 8.0 Hz), 5.40 (d, 5H,2J = 15.7 Hz, a-NC / 72Ar), 4.75 - 4.63 (m, 10H, b-NCH2Ar, c-NCH2Ar), 3.61 (d, 5H,2J = 13.0 Hz, d-NCH2Ar).13C{1H} NMR (DMSO-d6, 700 MHz): δ 205.9 (NCN), 205.4 (NCN), 166.1 (C=O), 166.0 (C=O), 138.1 , 137.2, 136.1, 134.6, 132.8, 132.1 , 132.0, 131.1, 130.7, 129.9, 129.7, 129.6, 129.5, 129.4,
[0183] 129.1 , 128.8, 127.3, 126.6, 125.6, 125.0, 124.7, 125.0, 124.7, 115.1 , 114.5, 113.1 , 112.4,
[0184] 53.1 , 51.9, 51.2, 47.5. UV-Vis absorption spectrum in methanol: Local maxima at 298 nm, 321 nm, 336 nm, 408 nm, 453 nm, 514 nm.
[0185] Example 6N. Synthesis of [AU13(NHC)5Br2]X3where L is (di-benzoic acid-wingtip dimethylnapthalene-linker)NHC and X is a counterion (e.g., Cl, Br, BF4, or PFe)
[0186] Referring to the reaction of Example 6L, [AU13(L)5Br2]X3where L is (di-ethyl- benzoate-wingtip dimethylnapthalene-linker)NHC (17 mg, 2.61 μmol) afforded the title compound in 89% yield (14.6 mg). ESI-MS, calculated (m / z) for [C210H160AU13Br2N20O20]3+: 1999.87; found: 1999.88.
[0187] Example 7. Click reactions with azide functionalized nanoclusters
[0188] Example 7 A. General Click Reaction Protocol of [AU13(NHCBiomolecule)5Cl2]CI3[AU13(NHCR)5Cl2]CI3was dissolved in DMSO. The alkyne functionalized molecule (R- DIBO or R-BCN (BCN refers to (bicyclo[6.1.0]nonyne) where R = TEG-Me, Folate or Glucose (30 eq) was added and the solution was stirred at room for 3 hours, after which another addition (30 eq) was added, and the solution was stirred at room temperature overnight. The resulting solution was dried under reduced pressure, redissolved in H2O and purified by ultracentrifugation to remove excess alkyne moieties. Example 7B. Synthesis of [Au13(L)5Cl2]CI3where L is (DIBO-TEG-Me-wingtip benzyl- linker)NHC
[0189] This cluster was synthesized similar to Example 7A, by reaction of Azide-wingtip orthoxylyl-linker gold cluster [Au13bis-NHC)5Cl2]CI3with DIBO-TEG (see Example 1 P). ESIMS: Calc 3241.51 Found 3242.3099. UV-Vis: 286 nm, 331 nm, 341 nm, 422 nm, 431 nm, 459 nm, 525 nm.
[0190] Example 7C. Synthesis of [Au13(L)5Cl2]CI3where L is (1 ,8-naphthyl-linker DIBO-TEG-Me- wingtip) NHC
[0191] This title cluster (see Table 3) was synthesized similar to Example 7A, by reaction of gold cluster [Au13(bis-L)5Cl2]CI3where L is (Azide-wingtip 1 ,8-napthyl-linker with DIBO-TEG (see Example 1 P). ESI-MS: Calc 3324.87, Found 3325.56. UV-Vis: 291 nm, 335 nm, 345 nm, 426 nm, 432 nm, 459 nm, 511 nm.
[0192] Example 7D. Synthesis of [Au13(NHC)5Cl2]CI3where L is (Folate-DIBO-wingtip benzyl-linker TEG-Me-backbone)NHC
[0193] This cluster was synthesized similar to Example 7A, by reaction of [Au13(L)5Br2]X3where L is (4-azidobenzyl-wingtip orthoxylyl-linker TEG-Me-backbone)NHC with Folate- DIBO (see Example 1 L). UV-Vis: Folate-DIBO 287 nm, 360 nm, 462 nm.
[0194] Example 7E. Synthesis of [Au13(L)5Cl2]CI3where L is (Folate-BCN-wingtip benzyl-linker TEG-Me-backbone)NHC
[0195] This cluster was synthesized similar to Example 7A, by reaction of [[Au13(L)5Br2]X3where L is (4-azidobenzyl-wingtip orthoxylyl-linker TEG-Me-backbone)NHC with Folate-BCN (see Example 1 L). UV-Vis: Folate BCN in H2O 315 nm, 373 nm, 455 nm, 524 nm. FT-IR: Folate-BCN 728 cm"1, 762 cm"1, 821 cm"1, 838 cm"1, 974 cm"1, 982 cm"1, 1131 cm"1, 1602 cm"1, 1640 cm"1, 1701 cm"1, 3054 (broad) cm"1.
[0196] Example 7F. Synthesis of [Au13(L)5Cl2]CI3where L is (DIBO-TEG-Glucose-wingtip benzyl- linker)NHC
[0197] The title cluster was synthesized similar to Example 7A. Specifically, gold cluster [ [Au13(bis-L)5Cl2]CI3where L is (azide-wingtip orthoxylyl-linker)NHC (see Example 6D) was clicked with DIBO-TEG-glucose (see Example 1 K). The title product was characterized. UV- Vis (Water): characteristic absorbance at 286, 303, 329, 455 and 524 nm. ESI-MS: Calc 3881.43, Found 3881.38. Example 7G. Synthesis of [Au13(L)5X2] Y3where L is (DBCO-TEG-Pertuzumab-wingtip benzyl-linker)NHC
[0198] Referring to Fig. 3 (second reaction arrow), the title cluster was synthesized similar to Example 7A. [Au13(NHCR)5Cl2]CI3was dissolved in DMSO. The DBCO-Pertuzumab was prepared according to Example 1 R. For DBCO-Pertuzumab click reactions, to a solution of DBCO-Pertuzumab in PBS at 10 μM concentration was added [Au13(NHCR)5Cl2]CI3(40 equiv.; 400 μM final concentration). The reaction mixture was incubated overnight at 37 °C, rocking end-over-end. Reaction was quenched with the addition of N3-PEG3-Alcohol (50 equiv.)( PEG refers to triethylene glycol) and was incubated overnight at 37 °C, rocking endover-end. The reaction was purified by protein G column purification to remove excess cluster molecules. The title product was characterized using Western blotting (Fig. 4) and size exclusion chromatography (SEC) (see Fig. 5).
[0199] Referring to Fig. 4, a Western blot is shown comparing DBCO-Pertuzumab and the title product click reaction, labeled as AuNC-Pertuzumab. The blot was probed with total protein stain and Immunoblot (IB) analysis with a goat anti-human-IgG detected the antibody. Regarding the click reaction data, see the presence of darker bands at a higher molecular weight, indicative of AuNC-Pertuzumab product (title product).
[0200] Referring to Figure 5, a size exclusion chromatography (SEC) chromatogram of the purified title product (labeled as AuNC-Pertuzumab) measuring absorbance at 280nm to detect protein products. The AuNC-Pertuzumab trace line (black line) shows title product eluting at a retention time of 3.3 minutes (indicates higher molecular weight product); the DBCO-Pertuzumab trace line (dark grey) shows the click reaction antibody starting material eluting at a retention time of 4.4 minutes; the AuNC trace line (light grey) shows the click reaction Au13(NHCR)5Cl2]CI3starting material (labeled AuNC) eluting at a retention time of 5.7 minutes.
[0201] EQUIVALENTS
[0202] It will be understood by those skilled in the art that this description is made with reference to certain embodiments and that it is possible to make other embodiments employing the principles of the invention which fall within its spirit and scope.
[0203] Table 1. Structural Formula of Compounds
[0204] Table 2. Structural formula of gold complexes
[0205] Table 3. Structural Formulae of Nanoclusters, where X is a monovalent ligand and Y is a counterion, and Y can be the same or different than X.
[0206]
Claims
We claim:
1. A metal nanocluster comprising a plurality of ditopic ligands comprising a b / sN- heterocyclic carbene ligand and at least one water soluble moiety.
2. The metal nanocluster of claim 1 , further comprising gold.
3. The metal nanocluster of claim 1 , further comprising AU13.
4. The metal nanocluster of claim 1 , wherein the at least one water soluble moiety comprises a polyether, a carboxylic acid, a carboxylate, an ammonium group, a sugar, or a protein.
5. The metal nanocluster of claim 4, wherein the polyether moiety comprises a polyethy leneg lycol .
6. The metal nanocluster of claim 4, wherein the polyether moiety is triethyleneglycol.
7. The metal nanocluster of claim 4, wherein the carboxylic acid is a benzoic acid.
8. The metal nanocluster of claim 4, wherein the carboxylic acid is a metal benzoate.
9. The metal nanocluster of claim 4, wherein the sugar is glucose, galactose, mannose, lactose, maltose, or maltotriose.
10. The metal nanocluster of claim 4, wherein the protein is an antibody.
11. The metal nanocluster of claim 10, wherein the antibody is Pertuzumab.
12. The metal nanocluster of any one of claims 1 to 11 , wherein the water soluble moiety is located on the wingtips of the bisNHC ligands.
13. The metal nanocluster of any one of claims 1 to 12, wherein the water soluble moiety is located on the backbone of the bisNHC ligands.
14. The metal nanocluster of any of claims 1 to 13, wherein the nanocluster further comprises a targeting ligand.
15. The metal nanocluster of claim 14, wherein the targeting ligand is a derivative of folic acid.
16. The metal nanocluster of any of claims 1 to 15, further comprising at least one clickable group.
17. The metal nanocluster of claim 16, wherein the clickable group is an azide.
18. The metal nanocluster of any of claims 1 to 17, wherein the nanocluster is selected from:[AU13(L)5X2]Y3 where L is (benzyl-wingtip orthoxylyl- linker TEG-Me- backbone)NHC,(simplified by showing only one L)(simplified by showing only one L)[Aui3(L)5X2]Y3 where L is (4-azidobenzyl-wingtip orthoxylyl-linker TEG-Me- backbone)NHC,(simplified by showing only one L)(simplified by showing only one L)[AU13(L)5X2]Y3where L is (d i-ethyl-benzoate-wi ngtip ortho-xylyl-linker)NHC,X— — X(simplified by showing only one L)(simplified by showing only one L)(simplified by showing only one L)[AU13(NHC)5X2]Y3 where L is (di-benzoic acid-wingtip 1 ,8-dimethylnapthalene- linker)NHC,(simplified by showing only one L)(simplified by showing only one L)(simplified by showing only one L)(simplified by showing only one L)(simplified by showing only one L)[AU13(L)5X2]Y3where L is (DIBO-TEG-Me- wingtip 1 ,8-naphthyl-linker)NHC,(simplified by showing only one L)[Au 13( 1)5X2] Y3 where L is(simplified by showing only one L)(simplified by showing only one L), where X is a monovalent ion and Y is a monovalent counterion.
19. The metal nanocluster of claim 18, wherein X is a halide.
20. The metal nanocluster of claim 19, wherein X is a chloride, or bromide.
21. A complex comprising gold, and bisNHC ligands bearing a water soluble moiety.
22. The complex of claim 21 , wherein the complex is selected from:Benzyl-wingtip naphthyl-linker TEG-Me- backbone NHC(AuBr)2,4-azidobenzyl-wingtip orthoxylyl-linker TEG backbone complex NHC(AuBr)2,Benzyl-wingtip orthoxylyl-linker TEG backbone NHC(AuCI)2.
23. The metal nanocluster of any one of claims 1 to 20, or complex of claim 19 or 20, wherein the compound is photoluminescent or electroluminescent.
24. A photosensitizer comprising the nanocluster of any one of claims 1 to 20, or complex of claim 21 or 22.
25. A method of photoredox catalysis comprising adding the metal nanocluster of any one of claims 1 to 20, or the complex of claim 21 or 22, to a reaction mixture, and applying radiation to the reaction mixture.
26. The method of claim 25, wherein radiation comprises visible light, UV light, heat, Gamma radiation or X-ray.
27. A photosensor comprising the metal nanocluster of any one of claims 1 to 18, or the complex of claim 21 or 22.
28. A solar cell comprising the metal nanocluster any one of claims 1 to 20.
29. An electroluminescent device that comprises a metal nanocluster any one of claims 1 to 20.
30. A photoluminescent device that comprises the metal nanocluster of any one of claims 1 to 20, or the complex of claim 21 or 22.
31. A method of producing photoluminescence, comprising the steps of: providing a photoluminescent metal nanocluster of any one of claims 1 to 20, and applying radiation to the nanocluster whereby the nanocluster photoluminesces.
32. A method of imaging cells in tissue in a subject comprising: administering to the subject a metal nanocluster of any one of claims 1 to 20, and applying radiation to cells that are desired to be imaged, wherein the nanoclusters in the cells photoluminesce.
33. A method of imaging cells in tissue comprising: disposing the metal nanocluster of any one of claims 1 to 20 into cells, andapplying radiation, whereby the nanoclusters in the cells photoluminesce.
34. A method of imaging cells in vitro comprising: disposing the metal nanocluster of any one of claims 1 to 20 into cells, and applying radiation, whereby the nanoclusters photoluminesce.
35. A method of imaging cells in vitro comprising: disposing the metal nanocluster of any one of claims 1 to 20 into cells, and applying radiation, whereby the nanoclusters can be detected by magnetic resonance imaging (MRI).
36. A method of killing cells, comprising disposing the nanocluster of any one of claims 1 to 20 into cells, and applying radiation, whereby the cells die.
37. The method of any one of claims 31 to 36, wherein radiation comprises visible light, UV light, heat, Gamma radiation, orXray.
38. A method of producing electroluminescence, comprising the steps of: providing a metal nanocluster of any one of claims 1 to 20 and applying a voltage across the nanocluster whereby the nanocluster electroluminesces.
39. A method of photocatalysis or electrocatalysis comprising a metal nanocluster of any one of claims 1 to 20.
40. The method of any one of claims 31 to 36, wherein the metal nanocluster is stable in vivo, in aqueous media, in bodily fluids, and in simulated bodily fluids.
41. A biosensor comprising the metal nanocluster of any one of claims 1 to 20.
42. A radiation therapy adjuvant comprising the metal nanocluster of any one of claims 1 to 20.
43. A photodynamic therapy method comprising a step of administering the metal nanocluster of any one of claims 1 to 20, and using light to excite the metal nanocluster.
44. An X-ray photodynamic therapy method comprising a step of administering the metal nanocluster of any one of claims 1 to 20.
45. A cancer treatment therapy comprising a step of administering the metal nanocluster of any one of claims 1 to 20.
46. A bioimaging method comprising a step of administering the metal nanocluster of any one of claims 1 to 20.
47. A method of electrocatalysis comprising employing the metal nanocluster of any one of claims 1 to 20 as an electrocatalyst.
48. The method of claim 47 wherein the metal nanocluster is in solution or on a support.
49. A method of electrocatalysis comprising employing the metal nanocluster of claims 1 to 20.
50. The method of claim 49 wherein the metal nanocluster is a soluble electrocatalyst.
51. The metal nanocluster of any of claims 1 to 17, wherein the nanocluster is selected from:[Au 13(L)5X2]Y3 where L is (benzyl-wingtip orthoxylyl-linker TEG-Me-backbone)NHC, [AU13(L)5X2]Y3 where L is (Benzyl-wingtip napthyl-linker TEG-Me- backbone)NHC,[Au 13(L)5X2]Y3 where L is (4-azidobenzyl-wingtip orthoxylyl-linker TEG-Me-backbone)NHC,[AU13(L)SX2]Y3 where L is (di-benzoic acid-wingtip ortho-xylyl-linker)NHC,[Au13(NHC)5X2]Y3 where L is (4-Azidobenzyl-wingtip naphthyl-linker TEG-Me backbone)NHC,[Au13(NHC)5X2]Y3 where L is (di-benzoic acid-wingtip 1 ,8-dimethylnapthalene-linker)NHC,[Au 13(L)5X2]Y3where L is (DIBO-PEG4-Glucose-wingtip benzyl-linker)NHC,[Au 13(L)5X2]Y3 where L is (DIBO-TEG-Me- wingtip 1,8-naphthyl-linker)NHC,[Au 13(L)5X2]Y3 where L is (DIBO-TEG-Me-wingtip benzyllinker)NHC, or[Au 13(L)5X2]Y3 where L is (DIBO-TEG-Pertuzumab-wingtip benzyl-linker)NHC, where X is a monovalent ion and Y is a monovalent counterion.
